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ABSTRACT 
 
Fibronectin-binding protein A (FnBPA) plays a crucial role in the pathogenesis 
of Staphylococcus aureus by binding to the host proteins fibronectin (Fn) and fibrinogen 
(Fg) found in the extracellular matrix and blood plasma, initiating tissue adherence, host 
cell invasion, and attachment to implanted materials. Although the interactions between 
FnBPA and host ligands Fn and Fg have been studied extensively using domains or 
segments of the proteins, the combined regulation of multiple ligands binding to FnBPA 
is poorly understood, and the underlining molecular mechanism of invasion is still not 
clear. Here, structure–activity relationships and regulation of FnBPA-dependent host 
interaction were investigated using a set of biochemical and biophysical techniques. 
With surface plasmon resonance (SPR) as the primary approach, the binding studies 
were performed using purified recombinant and native full-length proteins as well as a 
non-purified system (blood plasma). By capturing full-length FnBPA on a biosensor in 
the same orientation as on the S. aureus cell wall, SPR binding analysis show that 
circulating plasma can bind tightly to FnBPA with stronger affinity than that of Fn- and 
Fg-binding, also Fn and Fg can bind to FnBPA simultaneously. The results demonstrate 
that Fg binds to full-length FnBPA with 100-fold stronger affinity than previously 
reported, presumably through unidentified binding sites in both Fg and FnBPA. 
Furthermore, the structure analysis and binding study indicate that Fg conformation and 
structural orientation of surface-associated FnBPA are critical for high-affinity 
interaction between Fg and FnBPA. The proteolytic cleavage of N1 domain and low pH 
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affect the folding of N1 domain and Fg-binding activity of FnBPA, suggesting N1 fold-
back conformation is required for fully active Fg-binding.  Moreover, the strong 
interaction between FnBPA and Fn induces conformational changes in Fn and exposes 
cryptic integrin binding sites, resulting in an enhanced Fn-α5β1 interaction for host cell 
signaling. In addition, SPR binding analysis indicates that amino acid substitutions, 
which reflect disease-related polymorphisms found in FnBPA-9, alter the Fn-binding 
reaction and, in turn, impact the formation and function of the ligand complex within 
specific pathological contexts. The regulation and biological consequences of FnBPA 
ligand-binding activities revealed in this study are likely to have important implications 
for S. aureus interactions with the host in vivo. This study provides mechanistic insights 
into the FnBPA-dependent ligand binding, activation, and host cell signaling.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1. Overview 
The opportunistic pathogen Staphylococcus aureus is highly human adaptive and 
has evolved to exploit host proteins to establish infections and for survival. Many of 
these pathological processes are facilitated by MSCRAMM (microbial surface 
components recognizing adhesive matrix molecules) on the staphylococcal surface.1-2 
Through the MSCRAMM family of proteins, bacteria bind to the specific molecules 
fibronectin (Fn) and fibrinogen (Fg) in the extracellular matrix (insoluble form) and 
blood plasma (soluble form). There are two major biological consequences of such 
binding events: first, it can mediate bacterial adherence to host tissue or protein-coated 
device materials, and second, it can help accumulate plasma proteins onto the bacterial 
surface to invade host cells and avoid immune recognition.3 
To date, over 100 bacterial Fn-binding proteins (FnBPs) have been reported.4 The 
Fn-binding protein A (FnBPA) of S. aureus was the first MSCRAMM protein 
characterized that binds Fn,5-6 a glycoprotein component of host extracellular matrix 
(ECM) and plasma. The multiple functions of FnBPA were later discovered by its ability 
to engage fibrinogen (Fg) in wounds and blood,7 as well as elastin in connective tissue.8 
FnBPA is present in all clinical isolates and is upregulated during the transition from 
commensal state to invasive infections.9 It plays a critical role in development of 
infectious diseases such as endocarditis and mastitis.10-11 In an S. aureus experimental 
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endocarditis model, it was shown that the Fg- and Fn-binding abilities of FnBPA 
synergistically promote valve infection and endothelial invasion.12-13 A substantial body 
of evidence suggests that FnBPA can also manipulate physiological functions of Fn to 
activate integrin signaling pathways for host cell invasion,14-16 thus contributing to 
pathogenesis, beyond mediating bacterial adhesion.17-20 A multi-country genomic study 
in Europe showed that a common methicillin-resistant S. aureus (MRSA) strain has 
become more transmissible and virulent, partially due to genetic recombination events in 
fnbpA.21 Recently, several studies found that polymorphisms in FnBPA are associated 
with cardiac device-related infection in S. aureus bacteremia.22-23 
Because of the clinical prevalence and virulent roles in adhesion, invasion, and 
evasion, FnBPA can potentially be targeted in approaches to prevent and treat S. aureus 
infection. However, FnBPA has the most sequence diversity among all S. aureus 
MSCRAMMs,24 and the emergence of new clonal types has created polymorphic 
variations in the gene,25 making it difficult to target as a vaccine.26 Therefore, detailed 
studies of how FnBPA binds to ligands and how the binding of multiple ligands 
contributes to adhesion and invasion are critical for understanding S. aureus 
pathogenesis, and they would greatly facilitate the development of anti-adhesin 
strategies. 
1.2. Structure and organization of FnBPA 
FnBPA has structural features that are common to other MSCRAMMs: a signal 
sequence at the N-terminus is followed by a ligand-binding A domain, and at the C-
terminus, there is a large repeat region that is followed by segments and an LPXTG motif 
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involving cell wall localization and anchoring (Fig. 1). However, unlike other 
MSCRAMM repeat regions, which function as structural support for the A domain, the 
repetitive sequences in FnBPA are intrinsically disordered and responsible for the Fn-
binding function of S. aureus; therefore, it is termed a Fn-binding repeat (FnBR). 
 
 
Figure 1. Domain organizations of FnBPA 
Mature sequence corresponding to the extracellular region of FnBPA. Polypeptide 
contains an A domain that is divided into the N1, N2, and N3 subdomains (domain 
similarity among strains are indicated), followed by a sequential arrangement of 11 Fn 
binding repeat (FnBR), the proline-rich (PR) and cell wall (W) spanning regions, and a 
C-terminal sortase A recognition motif (LPETG). Thrombin cutting site (R165), single 
tryptophan residue (W494), and other functional sites, as well as disease-related sites, are 
shown. Function of the shaded regions has not been identified. Sequence alignment of 
the six high-affinity Fn-binding repeats is shown with major clinically related variant 
residues underlined. Highlighted in cyan are residues within each repeat that bind to or 
are presumed to engage Fn. Domains are drawn to scale using IBS (Illustrator for 
Biological Sequences, http://ibs.biocuckoo.org) based on UniProt ID: P14738. 
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The N-terminal A domain of FnBPA plays a multifunctional role and is capable 
of binding Fg and elastin.7-8, 27 The A domain of FnBPA is predicted to contain three 
separately folded subdomains: N1, N2, and N3 (Fig. 1). The N2N3 subdomains were 
shown to be the minimal Fg-binding domain.7 The structure of N2N3 (FnBPA189–505) 
comprises two distinct domains dominated by β-strands connected by an eight-residue 
linker.28 The main N2–N3 interdomain contacts involve strands and loops from each 
domain. To date, no structural or ligand-binding information regarding the N1 
subdomain is available. However, it has been demonstrated that only a short sequence 
within the N1 subdomain is required for export and cell wall localization.29 Within the A 
domain, there is a thrombin cleavage site close to the boundary between subdomains N1 
and N2 of FnBPA.30 The hemophilic interaction between the A domains on adjacent cells 
is important for biofilm formation by some strains of MRSA.31-32 
FnBPA contains structured domains (N2N3 in A domain) that interact with Fg 
and intrinsically disordered regions that bind multiple Fn molecules. The synergy 
between disordered regions and structured domains increases the functional versatility of 
FnBPA.12 
1.3. FnBPA binding to fibronectin 
The binding of fibronectin (Fn) to S. aureus was first reported in 1978 by Pentti 
Kuusela from City of Hope National Medical Center in Duarte, California.33 Ten years 
later, two Fn-binding MSCRAMMs were identified in S. aureus, FnBPA and FnBPB, 
and the corresponding genes, fnbpA and fnbpB, respectively, were cloned and 
expressed.5, 34-36 During the past 30 years, the specific interaction between FnBPA and 
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Fn has been well characterized by a variety of biochemical, biophysical, and structural 
methods. The tandem β-zipper model37 was proposed to describe the high-affinity 
interaction. More importantly, the physiological relevance and biological consequences 
of this specific interaction have been investigated both in vitro and in vivo.38 
The Fn-binding activity of FnBPA was initially identified in repetitive sequences 
in the C-terminal region, termed Fn-binding repeats (FnBR). Subsequently, FnBR (Fig. 
1) was considered the key binding domain, based on structural analysis of the complex of 
Fn and a bacterial peptide.37, 39 The new boundary designation extended the number of 
potential Fn-binding repeats in FnBPA to 11, with six high-affinity binding repeats 
identified (~ 40 aa in length), including FnBPA-1 in the original A domain (Fig. 1).40 
Although not highly similar overall, the FnBRs contain several short conserved Fn-
binding motifs (Fig. 1) that are arranged in the correct order to bind sequential modules 
in Fn.37 In this tandem β-zipper interaction, the disordered FnBRs adopt a highly 
extended conformation upon binding to Fn with very high affinity, even though each 
motif weakly engages the corresponding Fn module.40 
Fn is an essential multidomain protein that connects cells to the ECM via 
integrins, cell surface receptors. These glycoproteins play a significant role in cell 
adhesion, migration, growth, and differentiation, and they are essential for processes 
such as wound healing, angiogenesis, and oncogenesis.41-42 Two types of Fn are present 
in vertebrates: insoluble cellular Fn, which is secreted by various cells and assembled 
into a fibrous matrix in tissue; and soluble plasma Fn expressed by hepatocytes and 
circulated in blood at a concentration of about 0.3 mg/mL. Despite distinct 
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conformations (plasma Fn is highly compact in shape) and independent functions from 
extended cellular Fn, the inert plasma Fn, upon activation, can be incorporated into the 
ECM and accounts for a significant fraction of Fn in tissue ECM.43 
 
 
Figure 2. Domain organization of fibronectin 
Fn is a C-terminal disulfide-linked heterodimer. Shown here is the larger monomer with 
the extra domain A (EDA) and variable region (V). The protease-stable Fn fragments 
include the N-terminal domain (FnNTD) or fibrinogen binding region 1 (Fib-1), the 
gelatin-binding domain (FnGBD), the cell-binding domain (FnCBD), and fibrinogen 
binding region 2 (Fib-2). The integrin α5β1 “RGD” interaction motif and “synergy” site 
are shown. Two free cysteines (SH) were used to specifically label the FRET probes 
used in this study. Arrows indicate specific intramolecular interactions formed between 
domains of the FnNTD fragment and the distant FnCBD fragment. 
 
 
 
Fn is secreted as a disulfide-linked heterodimer that is modular in nature. 
Alternative splicing results in Fn monomers that are similar, but not identical, with only 
one monomer carries a variable region (V). Each Fn module is composed of three 
structurally defined repeating units termed FnI, FnII, and FnIII (Fig. 2). Several 
functional protease-stable Fn fragments are known, including the N-terminal domain 
(NTD), the gelatin-binding domain (GBD), and the cell-binding domain (CBD). The 
CBD harbors the canonical integrin α5β1, the “RGD” tripeptide interaction motif within 
the 10th FnIII module, and the “synergy site” in the 9th FnIII module. Fn serves as a 
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natural ligand for many other integrins, such as αvβ3, α4β1, and αIIbβ3, and their binding 
sites are mainly located in the CBD. Through CBD and the highly reactive NTD, which 
interacts with many biological molecules, Fn carries out adhesive functions, linking cells 
to the substrates. For soluble plasma Fn, however, due to its compact structure, many 
important binding sites are somewhat cryptic, and they are only exposed after 
conformational changes during processes such as fibril assembly.44 
1.4. FnBPA binding to fibrinogen 
The A domain of FnBPA is predicted to be made of three separately folded 
subdomains of N1, N2, and N3 (Fig. 1), which are similar to the Fg binding ClfA of S. 
aureus.45 Both FnBPA and ClfA use a minimal segment of the N2N3 subdomains to bind 
Fg at the C-terminus of γ-chain peptide (FgγC),7 although the mechanisms are 
different.28, 46 A recent structural analysis of the N2N3 domains of FnBPA (apo form and 
in complex with a Fg peptide) revealed that binding the FgγC peptide did not require a 
“latching” step,28 one of the common steps in the “dock, lock and latch” ligand-binding 
mechanism proposed for MSCRAMM.3 The FgγC peptide docks in a cleft between N2 
and N3, forming an additional β-strand that is parallel to the G’ strand in N3 in a β-zipper 
interaction.28 Such an interaction triggers translocation of the G’ strand in N3 to wrap 
around the FgγC peptide and interact with the N2 subdomain. This “locking” event only 
induces subtle conformation changes in the individual N2 and N3 subdomains.28 
Fg, also called factor I, is a large glycoprotein produced in the liver and also 
found in blood plasma. The major function of Fg is to form fibrin clots that prevent the 
loss of blood upon vascular injury. Fg plays a role in physiological and pathological 
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processes related to wound healing, tumor growth, and metastasis, as well as defense 
mechanisms. These functions are highly regulated in specific ways through interactions 
with a variety of proteins such as enzymes, membrane receptors, ECM molecules, lipids, 
and other small molecules.47 The 340-kDa Fg is composed of three polypeptide chains 
(α, β, and γ [Fig. 3]) that are arranged as a dimer with three domains: a central E domain 
and two peripheral D domains (FgD). Fg heterogeneity results from the glycosylation of 
β and γ chains, the phosphorylation of the α chain, polymorphisms in the α and β chains, 
and alternative splicing of the α and γ chains.48 The “tail” of the γ chain extends from the 
globular domain, which includes the glutamine and lysine residues involved in factor 
XIIIa-catalyzed cross-linking (Fig. 3). The C-terminal γ-chain peptide is recognized by 
the platelet integrin αIIbβ3 during Fg-dependent platelet adherence and aggregation.49 Fg 
is also targeted by S. aureus, causing Fg-dependent cell clumping and tissue adherence.3 
FnBPA binds to the C-terminal end of the γ chain (FgγC peptide 
G397QQ399HHLGGAK406QAGDV411)28 overlapping with integrin αIIbβ3 binding sites. 
Within this region, there are γ chain cross-linking sites (Q399 and K406) through which 
two fragment D moieties covalently link and form a FgD dimer (Fig. 3). 
Approximately 75% of Fg is found at high concentration (~3 mg/mL) in blood 
plasma, and the remainder is distributed in interstitial fluid and lymph. The circulating 
plasma Fg can be deposited into the ECM with an altered conformation and then 
function as an ECM protein to facilitate cellular adhesion or the structural integrity of 
tissues. Recent studies have shown that Fg in cultured cell medium is incorporated into 
the ECM during the active secretion and assembly of Fn from fibroblasts. Functional 
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characterization of proteolytic Fn fragments have identified binding sites for Fg on the 
N-terminal domain of Fn (FnNTD) or fibrinogen binding region 1 (Fib1) and on 
fibrinogen binding region 2 (Fib2) (Fig. 2).50-51 Therefore, similar to Fn, Fg also joins Fn 
that function as both plasma and matrix proteins to perform their diversified functions 
and also targeted by FnBPA of S. aureus. 
 
 
Figure 3. Domain organization of fibrinogen 
Fg is formed by three pairs of α, β, and γ chains that are covalently linked to form a 
“dimer of trimers”. The polypeptides are oriented such that N-terminal ends of each 
monomer meet, while the coiled coil regions stretch out and end in a globular D domain 
The D domain (FgD) is consist of C-terminal parts of all three chains. FnBPA binds to 
the C-terminal end of the γ chain (FgγC peptide GQQHHLGGAKQAGDV) overlapping 
with one of the integrin αIIbβ3 binding sites. Within this region, there are γ chain cross-
linking sites (bolded residues, Q399 and K406) through which two fragment D moieties are 
covalently linked to form a FgD dimer. The elongated variant has a 20 aa sequence 
insertion at the end (γ’434–453). Amino acid numbers are based on UniProt sequences 
(P02671 for Aα, P02675 for Bβ, and P02679 for γ chain), from which the signal peptide 
sequence was deduced. 
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1.5. FnBPA-dependent host cell invasion 
While S. aureus is typically considered an extracellular pathogen, intracellular S. 
aureus is associated with several chronic and reoccurring infections,12, 52-53 and infection 
can be established, even in the presence of the vancomycin.54 S. aureus can invade 
several types of host cells, and while this process requires FnBPA and integrins, it does 
not usually involve phagocytosis.38 Thus, S. aureus internalized by non-professional 
phagocytes represents a bacterial reservoir that is protected from antibiotics and innate 
host defense systems. It has been suggested that tandemly arranged FnBR enables a 
single FnBPA molecule to interact with multiple Fn molecules to engage an array of α5β1 
integrins, triggering a bacterial uptake.39 S. aureus only needs to express a low surface 
density of FnBPA to establish adhesion and initiate an invasion.18 
Integrins are essential metazoan heterodimeric glycoproteins that mediate cell 
adhesion, establish transmembrane connections to the cytoskeleton, and play an integral 
role in cell signaling pathways.55 Interestingly, integrins are common targets of 
pathogens, and they often participate in bacterial and viral adhesion to host cells.56 Two 
modes of microbial integrin recognition have been described: direct binding by bacterial 
surface proteins,57-59 or indirect binding via physiological ligands, such as Fn.16, 56, 60 The 
latter mode is used by S. aureus; specifically, FnBPA manipulates Fn function as a 
natural ligand for α5β1 integrin, activating endocytic pathways, ultimately resulting in the 
internalization of S. aureus by non-professional phagocytes.14, 18-20, 61 A single high-
affinity FnBR is sufficient for α5β1 integrin-dependent in vitro invasion of endothelial 
cells by S. aureus.18 
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1.6. Disease-related polymorphisms in FnBPA 
By comparing the fnbpA within the disordered FnBR region, several recent 
studies have found a correlation between cardiovascular infections caused by S. aureus 
and non-synonymous single nucleotide polymorphisms (SNPs) in FnBPA.22-23, 25 All 
SNPs within this region are located in the high-affinity Fn-binding repeats 9 (FnBPA-9) 
and 11 (FnBPA-11), mainly in FnBPA-9 (Fig. 1). Single and double substitutions 
(H782Q and K786N) were identified in clinical isolates in patients from two continents 
with infected cardiac device implants22-23 that exhibited a higher affinity for Fn, as 
measured by atomic force microscopy. Similar SNP variants (H782Q and K786I) were 
found in MRSA strains causing infective endocarditis.25 Some strains had an additional 
FnBPA-9 inserted or a more immunogenic motif substitution in FnBPA-11. Interestingly, 
this polymorphism was not found in strains isolated from patients with infected 
arthroplasties where the abscess exists within a sanctuary space.62 It seems that a certain 
“mutation” in FnBPA is selected during endovascular infections where the hemodynamic 
flow is a factor, and immobilized fibronectin molecules (on tissues or devices) are the 
dominant host ligand. 
1.7. Goals of the study 
Although the interaction between FnBPA and the host ligands Fn and Fg have 
been studied extensively using domains or segments of the proteins, the interplay, and 
regulation of multiple ligands binding to FnBPA at the same time is still poorly 
understood. Moreover, the underlining molecular events that lead to FnBPA-dependent 
invasion have remained elusive. With these in mind, the goals of this study were: first, 
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develop an expression and purification system to obtain full-length intact FnBPA; 
second, to carefully characterize the binding of FnBPA to host ligands, including human 
blood plasma; third, to understand the nature of structural changes induced by FnBPA 
and correlate these changes with quantitative and direct measurements of Fn–α5β1 
integrin interactions; and fourth, to understand how amino acid polymorphisms in Fn-
binding repeats impact the strength and formation of the binding complex within specific 
pathological contexts. 
1.8. Methods used in this study 
In this study, purified recombinant and native full-length proteins, as well as non-
purified blood plasma as materials, were utilized with surface plasmon resonance (SPR) 
and other biophysical and biochemical methods to investigate structure–activity 
relationships and regulation of FnBPA–host interactions. Circular dichroism (CD), 
steady-state fluorescence spectroscopy, dynamic light scattering (DLS), and fluorescence 
resonance energy transfer (FRET) were used to characterize and examine the 
conformational status of free or ligand-bound proteins in solution. For binding studies, 
isothermal titration calorimetry (ITC) and SPR were used to analyze thermodynamics 
and kinetics of the interactions, and monitor the complex formation in the presence of 
competing molecules. 
1.9. SPR as the main approach 
SPR occurs when surface plasmons (electromagnetic waves formed by electrons) 
propagate along the surface of a thin metal layer and give rise to the resonance.63 Biacore 
is a microfluidic surface-based biosensor platform that exploits SPR phenomena to 
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monitor molecular interactions in real time. This approach requires the attachment of one 
interacting partner to the surface of a sensor chip and then passing a sample with another 
interaction partner over it. The binding of molecules to the sensor surface generates a 
response that is proportional to the bound mass, and the binding of molecules in the bulk 
sample solution on the sensor surface can be detected with picomolar resolution. The 
signal is shifted by a binding event or induced conformational changes.64 The continuous 
registration of the signal makes it possible to characterize the binding mechanism and 
determine the association rate constant (kon or ka) and dissociation rate constant (koff or 
kd) as well as the binding affinity (KD, KD = koff /kon). Thermodynamic parameters can 
also be estimated by performing binding analyses at multiple temperatures. Aditional 
complex biological interactions can be investigated with sophisticated designs and 
comprehensive analyses. 
The Biacore assay is performed by injecting the analyte (the interaction partner in 
solution phase) over the sensor chip to which the ligand is immobilized (the interaction 
partner in solid phase) under a continuous flow of running buffer. Then, the sensor chip 
will be regenerated, which is the process of removing bound analyte from the surface, 
without inactivating the ligand, so that a new cycle of analysis can be conducted on the 
same active ligand surface. The binding response is measured in resonance units (RU), 
which are proportional to the concentration of bound molecules on the surface. Real-time 
binding data is recorded as a sensorgram, which shows the response (RU) as a function 
of time (second). 
SPR detects interactions that occur on the surface of a sensor chip. The specificity 
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of the interaction analysis is determined by the nature and properties of the molecule 
anchored to the sensor surface. There are three different approaches to attach a molecule 
onto the chip surface: (1) covalent immobilization, where the ligand is attached to a 
surface through a covalent chemical link, (e.g., the most commonly used amine coupling 
approach involves a chemical reaction between available primary amine group[s] on the 
ligand and reactive carboxylic group on the chip surface); (2) high-affinity capture, 
where the ligand is attached by non-covalent high-affinity interactions, with another 
molecule that is usually covalently immobilized; and (3) hydrophobic adsorption. 
Among many available surface preparation techniques, amine immobilization is 
the most widely applied and accepted approach. However, amine coupling is a random 
process, and therefore, the orientation of the immobilized molecule cannot be 
determined. In addition, the chemical modification of the ligand can potentially affect 
binding activity. This is particularly true for proteins that have multiple domains and 
contain several available amine groups. Also, attachment to the surface can introduce 
heterogeneity in the ligand population. Capturing approaches are alternative strategies to 
avoid inactivation and achieve homogeneous orientations of the ligand, which is 
important for experimental design. Some common capturing approaches are streptavidin-
biotin capture, antibody-based capture, and tagged-based capture. Interactions between 
the ligand and capturing molecule should be strong enough to hold the ligand in place so 
that it does not detach from the surface during an analysis cycle. Recombinant proteins 
used in the binding studies are often tagged for affinity purification and identification. 
Following the same principle, tagged recombinant proteins can be captured (or tethered) 
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onto the sensor chip with high-affinity antibodies for the specific tag, such as poly-
histidine, glutathione S-transferase (GST), and Strep-tag II. 
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CHAPTER II  
MATERIALS AND METHODS* 
2.1. Plasmid construction 
Genomic DNA of S. aureus USA300 TCH1516 was used as a template to 
amplify the DNA encoding full-length FnBPA, which corresponded to amino acids 38–
981 and covered residues after the signal peptide to residues right before the LPXTG 
sortase cleavage motif. The initial construct was generated using a modified pET15b 
vector, which contains a C-terminal fusion to super-folder GFP (green fluorescent 
protein) that is cleavable by a TEV (Tobacco Etch Virus) protease, followed by a 6x His-
tag.65 This expression plasmid was further developed by adding a 2x StrepII-tag and a 
TEV protease cleavable site to the N-terminus of the FnBPA gene to generate a double-
tagged FnBPA construct. The resulting N- and C-terminal fusion vectors were linearized 
with BamHI and NheI (New England Biolabs), purified using a QIAQuick Gel 
Extraction kit (Qiagen), and used in subsequent infusion cloning reactions (Clonetech). 
All truncated FnBPA proteins were constructed using the same template plasmid DNA, 
with primers designed for an infusion cloning reaction using the Clonetech online tool. 
* Part of the material reported in this chapter is reprinted and adapted with permission from 
“Allosteric Regulation of Fibronectin/alpha5beta1 Interaction by Fibronectin-Binding MSCRAMMs” 
by Liang, X.; Garcia, B. L.; Visai, L.; Prabhakaran, S.; Meenan, N. A.; Potts, J. R.; Humphries, M. J.; 
Hook, M. PLoS One 2016, 11 (7), e0159118. CC by PLoS. Copyright 2016. 
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All constructs were verified by sequencing plasmid DNA. The primer sequences are 
listed in Table 1. 
 
Table 1. Oligonucleotides to generate tagged FnBPA constructs 
Name Designation Vector with n/c tag Primer sequence (5’-3’) 
ALC307 fnbpA38 
forward 
pET15b-GFPcHis AAGGAGATATACATATGTCAGAA
CAAAAGACAACTACA 
ALC308 fnbpA981 
reverse 
pET15b-GFPcHis GGTTTTCACCGCTAGCTTCAGATT
TCTTAGATTGTGG 
FnBPA38F fnBPA38 
forward 
pET15b-nStrepII^GFPcHis ATTTTCAGGGTGGATCCTCAGAA
CAAAAGACAACTACAGTAG 
FnBPA166F fnBPA166 
forward 
pET15b-nStrepII^GFPcHis ATTTTCAGGGTGGATCCACGGCA
TCAGAAAGTAAGCCACGTG  
FnBPA189F fnBPA189 
forward 
pET15b-nStrepII^GFPcHis ATTTTCAGGGTGGATCCGCGAAA
GTGGAAACGGGTACAGATG 
FnBPA511R fnBPA511 
reverse 
pET15b-nStrepII^GFPcHis GGTTTTCACCGCTAGCATTTTTCC
CATTTCCGTTCG 
FnBPA550R fnBPA550 
reverse 
pET15b-nStrepII^GFPcHis GGTTTTCACCGCTAGCTGATGAA
TCATATTCCTCTTC 
FnBPA672R fnBPA672 
reverse 
pET15b-nStrepII^GFPcHis GGTTTTCACCGCTAGCTTTCGTAT
CTTCAACTGTTGT 
FnBPA800R fnBPA800 
reverse 
pET15b-nStrepII^GFPcHis GGTTTTCACCGCTAGCAGGTTTG
TCTTTTTCTGTATC 
 
 
 
2.2. Recombinant FnBPA expression 
The modified pET15b-GFPcHis plasmid was transformed into Escherichia coli 
BL21 (DE3) Gold cells, while the pET15b-nStrepII^GFPcHis plasmid was transformed 
into the E. coli Rosetta (DE3) pLysS strain. A starter culture was prepared by inoculating 
50 mL of LB Miller medium with a frozen stock (~20 µl) of the expression strain, 
followed by growth overnight at 37 °C. The next day, 10 mL of starter culture was 
transferred into 1 L of growth media containing antibiotics and grown until the optical 
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density at 600 nm (OD600) reached 0.6–0.8. IPTG (isopropyl β-D-1-
thiogalactopyranoside) was then added to the culture at a final concentration of 0.5 mM 
to induce target protein expression for 3 h at 37 °C or overnight at 20 °C. Then, E. coli 
cells were collected by centrifugation at 5,000g for 10 min at 4 °C, washed with TBS 
buffer, pelleted, and stored at -80 °C. 
2.3. Protein purification 
2.3.1. Purification of recombinant FnBPA proteins 
The general purification strategy for recombinant FnBPA included nickel affinity 
chromatography, tag removal, “reverse” Nickel affinity, and, finally, gel filtration 
chromatography. For double-tagged FnBPA, an additional StrepTactin affinity 
chromatography step was included after the first nickel purification. The detailed steps 
are as follows: (1) thaw cell pellets and resuspend in Tris-buffered saline (TBS: 50 mM 
Tris, pH 7.5, and 300 mM NaCl) supplemented with cOmplete Protease Inhibitor 
Cocktail (Roche). (2) Lyse cells with 4–5 passes through an M-110P microfluidizer at 
20,000 psi. (3) Spin down the homogenate at 20,000g for 25 min at 4 °C. (4) Collect and 
filter the supernatant, and then add concentrated imidazole to a final concentration of 20 
mM. (5) Load the supernatant over the HisTrap-HP column (GE Healthcare) that was 
pre-equilibrated with HisTrap binding buffer (50 mM Tris, pH 7.5, 300 mM NaCl, and 
20 mM imidazole). (6) Wash column with HisTrap binding buffer until a steady A280 
baseline is reached. (7) Elute bound protein with two column volumes of HisTrap elution 
buffer (50 mM Tris, pH 7.5, 300 mM NaCl, and 200 mM imidazole). (8) Pool peak 
fractions and load them to a desalting column to exchange buffer to StrepTrap binding 
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buffer (100 mM Tris, pH 8.0, 150 mM NaCl, and 1 mM EDTA). (9) Load sample to the 
StrepTrap-HP column (GE Healthcare) and wash column with StrepTrap binding buffer 
until a steady A280 baseline is reached. (10) Elute bound protein with StrepTrap elution 
buffer (100 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, and 2.5 mM desthiobiotin). 
(11) Add β-mercaptoethanol to a final concentration of 5 mM to the StrepTrap column 
eluent, add His-tagged TEV protease (10 units of TEV protease per mg of protein), and 
incubate for 2 h at room temperature and then overnight at 4 °C. (12) Filter the TEV-
treated protein sample and load onto a pre-equilibrated HisTrap-HP column. (13) Collect 
the flow-through fraction, which contains the protein with the tag removed. (14) 
Concentrate and filter the sample using a 0.22 micron filter , and then pass it over a gel 
filtration column equilibrated with TBS (20 mM Tris, pH 7.5, and 100 mM NaCl). (15) 
Store the purified protein at -80 °C in the presence of 10% glycerol. 
2.3.2. Thrombin treatment of FnBPA and isolation of fragment 
  Tag-free FnBPA was incubated with 60 U thrombin and incubated at 37 °C for 2 
hours. Thrombin was removed from the mixture using a Benzamidine column (GE 
Healthcare). FnBPA fragments were further isolated using a gel filtration column. 
Tagged full-length FnBPA38–981 was cut with thrombin, and then the mixture was diluted 
and injected onto the anti-His mAb sensor chip to capture His-tagged FnBPA fragments 
(FnBPA166–981) for SPR analysis. 
2.3.3. Purification of native Fn 
 Human Fn was purified from freshly drawn citrated plasma (Gulf Coast Regional 
Blood Center, Houston, TX) using gelatin affinity chromatography combined with 
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arginine affinity chromatography, as described previously.66 Fn was stored at 4 °C in 
TBS (50 mM Tris-HCl, pH 7.4, and 150 mM NaCl), and used within one month. The Fn 
dimer concentration was calculated from the optical density at 280 nm with EC280 (1%) = 
12.8 and a molecular weight of 500 kDa. 
 
 
Table 2. Proteins and peptides used in this study 
   Description Source 
   
FnBPA38–981 Recombinant full-length FnBPA This work 
FnBPA38–800 Recombinant of FnBPA (aa 38–800) This work 
FnBPA38–672 Recombinant of FnBPA (aa 38–672) This work 
FnBPA38–609 Recombinant of FnBPA (aa 38–609) This work 
FnBPA38–550 Recombinant of FnBPA (aa 38–550) This work 
FnBPA38–511 Recombinant of FnBPA (aa 38–511, A domain) This work 
FnBPA166–550 Recombinant of FnBPA (aa 166–550, thrombin-cut) This work 
FnBPA-3 peptide Synthetic peptide of FnBPA-3 This work 
FnBPA-9 peptide Synthetic peptide of FnBPA-9 This work 
FnBPA-10 peptide Synthetic peptide of FnBPA-10 This work 
Fg Native fibrinogen purified from human plasma Enzyme Research 
FgD 
FgD dimer 
Proteolytic D-fragment of fibrinogen 
Cross-linked fibrin degradation by plasmin 
Millipore 
Hyphen BioMed 
Fn Native fibronectin purified from human plasma  This work 
FnNTD N-terminal domain of Fn Sigma 
FnGBD GBD of Fn Sigma 
FnCBD CBD of Fn Millipore 
Anti-Fn pAb  Polyclonal rabbit anti-human Fn ICN Pharmaceuticals, 
Anti-Fg pAb Polyclonal rabbit anti-human Fg Dako Cytomation 
Thrombin Protease purified from bovine plasma GE Healthcare 
Integrin α5β1 Recombinant ecto domains  Coe67 
Integrin αIIbβ3 Native receptor purified from human platelets Enzyme Research 
 
 
 
2.4. Other materials 
The Fn-binding repeats of FnBPA (FnBPA-1, FnBPA-3, FnBPA-5, FnBP-9, 
FnBPA-10 and FnBPA-11) were expressed as GST fusion proteins and purified using the 
procedure described by Meenan et al.40 The FnBPA-10 peptide was obtained from the 
laboratory of Prof. Jennifer R. Potts. BSA (bovine serum albumin) and heparin sodium 
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(from porcine intestinal mucosa, 17,000–19,000 Da) were obtained from Sigma. Other 
materials are listed in Table 2. 
2.5.  SPR-based binding assay 
Surface plasmon resonance-based binding experiments were performed at 25 °C 
on a Biacore 3000 or T200 instrument (GE Healthcare/Biacore, Uppsala, Sweden). The 
sensorgrams are shown in a format of “analyte → ligand,” in that various forms of 
soluble analyte (different concentration or mixtures with other molecules) were injected 
onto an immobilized ligand surface. 
2.5.1. Sensor surface preparation 
The protein ligands were covalently coupled to research-grade sensor chips (GE 
Healthcare) using an amine coupling kit containing N-(3-Dimethylaminopropyl)-N′-
ethylcarbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and 
ethanolamine (pH 8.5) (GE Healthcare/Biacore AB). During immobilization, phosphate 
buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 8.06 mM Na2HPO4 and 1.94 mM 
KH2PO4, pH 7.4) was used as running buffer, with a flow rate of 5 μL/min. The optimal 
immobilization condition for each protein was determined by a pH scouting experiment. 
Based on the scouting results and desired surface densities, various conditions (pH and 
concentration) were applied to each protein for the immobilization; they are listed in 
Table 3. The immobilization steps are: the flow cell surface was first activated by 
injecting EDC/NHS, followed by a protein amine reaction, and finally, the surface was 
deactivated with ethanolamine. A reference surface was made with activation and 
deactivation steps without coupled protein. 
For the binding assay using the capture approach, approximately 10,000 RU of 
anti-His mAb (GE Healthcare/ Biacore) or StrepMAB-Immo (IBA GmbH) was 
immobilized on a CM5 chip to reversibly capture the fusion protein containing the His-
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tag or Strep-tag. A surface with antibody immobilized and without captured ligand was 
used as a reference surface. 
 
Table 3. Conditions for immobilization of proteins for Biacore binding experiments 
Ligand Concentration buffer Chip Density 
Anti-His mAb 10 μg/mL 10 mM sodium acetate, pH 5.0 CM5 11,000 
StrepMAB-Immo 20 μg/mL 10 mM sodium acetate, pH 5.0 CM5 10,000 
Fg 10 μg/mL 10 mM sodium acetate, pH 5.5 CM4 2700 
FgD 5 μg/mL 10 mM sodium acetate, pH 5.0 CM4 900 
FgD dimer 20 μg/mL 10 mM sodium acetate, pH 5.5 CM4 1000 
FnNTD30k 20 μg/mL 10 mM sodium acetate, pH 5.5 CM3 2300 
FnBPA 10 μg/mL 10 mM sodium acetate, pH 4.5 CM3 700 
Integrin α5β1  10 μg/mL 10 mM sodium acetate, pH 4.8 CM5 1400 
BSA 25 μg/mL 10 mM sodium citrate, pH 5.0 CM5 5000 
 
 
 
2.5.2. Binding studies 
 Frozen Fg stocks (about 10 mg/ml in 20 mM sodium citrate-HCl, pH 7.4) were 
thawed in a 37 °C water bath without any agitation and stored at room temperature 
before use. Other soluble proteins were prepared by dialysis using Slide-A-Lyzer MINI 
Dialysis Units or spin desalting columns with the proper molecular weight cutoff 
(Thermo Fisher Scientific). The peptide was dissolved in PBS, and the concentration was 
determined using the absorbance at 205 nm.68 
To capture the tagged protein, a flow rate of 20 µL min-1 was used to inject the 
ligand until the desired density was reached, and then the surface was stabilized for 3 
min before performing a binding experiment. A flow rate of 30 or 50 µL min-1 was used 
for all binding experiments. To regenerate the ligand surface, the captured protein was 
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removed by a 15-s injection of 10 mM glycine (pH 1.7). For the Fn–integrin interaction, 
the integrin surface was regenerated to remove bound Fn by injecting 1 M NaCl for 1 
min. 
2.5.3. Data analyses 
All SPR responses were baseline corrected by subtracting the systematic noise 
from the corresponding reference surface. Double-referenced SPR response curves (with 
the buffer blank run also subtracted) were used for affinity determination. 
For steady-state interactions, the equilibrium response of each injection was 
collected and plotted as a function of the concentration of injected protein. A one-site 
binding (hyperbola) model was fit to the data (GraphPad Prism 4, GraphPad Software, 
Inc.) to obtain the equilibrium dissociation constant KD. Non-equilibrium data were 
globally fit to a 1:1 Langmuir binding model using BIAevaluation software (Version 
4.1). Association and dissociation rate constants, ka and kd, were obtained from the fits, 
and the dissociation constant, KD, was derived (KD = kd / ka). 
Kinetic constants were obtained from fitting the curve to a predefined bivalent 
analyte model using BIAevaluation software (Version 4.1). Heterodimeric Fn has two 
identical binding sites for integrin α5β1. The reaction between soluble Fn analyte (A) and 
immobilized integrin ligand (L) can be described by 
A + L 
𝑘𝑑1
↔ 
𝑘𝑎1
 AL + L 
𝑘𝑑2
↔ 
𝑘𝑎2
 AL2 
Binding to the first ligand is described by a single set of rate constants (ka1, kd1), 
so that the two sites on the analyte are equivalent in the first binding step. Binding of the 
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second ligand is described by the second set of rate constants (ka2, kd2), which are 
reported in the unconventional units of RU-1s-1. The first set of rate constants was used to 
calculate the dissociation constant KD (KD = kd1/ka1). 
2.6. ELISA-type binding assays 
Enzyme-linked immunosorbent assay (ELISA) experiments were conducted at 
room temperature, and each sample was assayed in triplicate. The immunoassay 
microplate Immulon 2HB (Thermo Scientific, Waltham, MA) was coated with 2 µg 
integrins dissolved in TBS for 1 hour. The plate was then blocked for 1 h with 1% (w/v) 
BSA in a buffer “A” (TBS with 1 mM MnCl2). Citrated plasma (stored at -20oC for less 
than 6 months) was quickly thawed at 37 °C and centrifuged to remove aggregates. The 
supernatant was diluted 10-fold in buffer “A” and then mixed with varying 
concentrations of the FnBPA-10 peptide to a final concentration of 5% plasma. The 
sample mixtures were added to the plate and incubated for 1 h. The plate was washed 
three times with buffer “B” (TBS with 1 mM MnCl2, and 0.05% Tween-20) before the 
addition of the rabbit anti-Fn antibody. Following the wash with buffer “B,” AP-
conjugated goat-anti-rabbit IgG (BioRad, Hercules, CA) was added to the plate and 
incubated for 1 h. All antibodies were diluted 2000-fold in buffer “B” containing 1% 
BSA. Alkaline phosphatase substrate pNPP (para-Nitrophenylphosphate, Pierce) was 
added after washing, and the absorbance was measured at 405 nm using a Thermo Max 
plate reader (Molecular Devices, Sunnyvale, CA). 
2.7. Isothermal titration calorimetry 
Experiments were performed at 25 °C with a MicroCal PEAQ-ITC instrument 
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 (Malvern) in PBS (137 mM NaCl, 2.7 mM KCl, 8.06 mM Na2HPO4 and 1.94 mM 
KH2PO4, pH 7.4). The protein concentration was determined using the absorbance at 280 
nm and the calculated extinction coefficient. For Fg and Fn, dimer concentrations were 
used. Each titration began with a 0.4-µl injection followed by 4 µl injections. Each 
injection (at a speed of 0.5 µl/s) was spaced at 150-s intervals at a stirring speed of 600 
rpm. Binding isotherms were fit to a One Set of Sites binding model using MicroCal 
PEAQ-ITC Analysis Software (version 1.1.0). 
2.8. Circular dichroism spectroscopy 
CD measurements were carried out at ambient temperature on a Jasco J-720 
spectropolarimeter (Easton, MD) in the near-UV region (250–350 nm) with a 1-cm cell, 
and in the far UV region (190–250 nm) with a 0.2-mm cell. Ten scans were collected and 
averaged at a scan speed of 200 nm min-1, with a time constant of 1 s and bandwidth of 1 
nm. The data were reported as an original CD signal (mdeg) or mean residue ellipticity, 
which was calculated based on the measured CD signal and the mean residue molecular 
weight of the protein sample (for Fn, it is 110). The spectra of the protein solution were 
background-corrected with the CD signal obtained from the buffer. 
2.9. Steady-state fluorescence spectroscopy 
Fluorescence spectra were measured using spectrofluorimeter LS 50B (Perkin-
Elmer). Two excitation wavelengths were used to excite intrinsic fluorescence: 280 nm 
(excite both Tyr and Trp ) and 295 nm (excite only Trp). Fluorescence emission was 
measured in the 300–420 nm wavelength region, with bandwidths of both slits set to 5 
nm. Each fluorescence spectrum was the average of three measurements, with a scan 
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speed of 300 nm/min. All spectra were corrected for background fluorescence by 
subtracting the appropriate blanks.  
2.10. Dynamic light scattering 
DLS measurements were performed using the DynaPro Titan Ambient laser unit 
(Wyatt Technology Corporation) with a wavelength at 828.5 nm and 10% to 12% laser 
power. Samples were dissolved in TBS and filtered through a 0.22-μm filter to eliminate 
any particles. Fn concentration was maintained at 0.8 mg ml-1 (1.6 μM as dimer) in TBS 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl) for the conditions tested. After equilibration at 
room temperature for 15 to 30 min, the samples were measured three times, with each 
measurement lasting 100 seconds (10 acquisitions, 10 seconds each). Data analyses were 
performed using Dynamics V6 software. 
2.11. Fluorescence resonance energy transfer 
Fluorescent labeling of human plasma Fn was performed at room temperature as 
described previously.69 The fluorescent probes used in this study were purchased from 
Molecular Probes. Briefly, fresh purified human plasma Fn at 1.2 mg ml-1 in TBS was 
partially denatured in 4 M GdnHCl (Sigma) for 15 min to expose free cysteines in the Fn 
dimer. The denatured Fn was mixed with thiol-reactive Alexa Fluo 546 C5-maleimide 
(AF546, ~15-fold molar excess over Fn monomer concentration) and incubated for 2 h 
with gentle rocking. The acceptor fluorophore, AF546-conjugated Fn (~0.9 mg ml-1), 
was labeled with a second probe, the amine-reactive Alexa Fluor 488 carboxylic acid-
succinimidyl ester-mixed isomers (AF488, ~20-fold molar excess). After each labeling 
reaction, the unbound dye was removed using a PD-10 desalting column (GE 
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Healthcare). The labeling ratios were ~8 AF488 donors and ~4 AF546 acceptors in each 
Fn dimer. 
FRET between the donor- and acceptor-labeled Fn was measured using 
spectrofluorimeter LS 50B (Perkin-Elmer) at room temperature with an excitation 
wavelength at 493 nm. The sensitivity of the FRET response to Fn unfolding was 
evaluated under a mild denaturant (up to 2 M GdnHCl). Measurements of MSCRAMM-
induced FRET within Fn were performed by titrating 0.5, 2 or 5 µl of 50 µM FnBPA-10 
into 500 µl of labeled Fn. Subsequently, the emission spectra collected for each titration 
were recorded and normalized to the donor emission peak so that changes were only 
reflected by changes in the acceptor peak. Control experiments were conducted using an 
equimolar solution of donor-labeled Fn with acceptor-labeled Fn in the presence and 
absence of 2 M GdnHCl to confirm the absence of energy transfer between adjacent Fn 
molecules in solution. 
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CHAPTER III 
RESULTS* 
3.1. Double-tagged full-length FnBPA shows Fg- and Fn-binding activities 
Initially, I constructed a C-terminal tagged full-length FnBPA using a modified 
pET15b vector that contains a TEV protease cleavable C-terminal fusion to GFP, 
followed by a 6×His-tag. The gel filtration chromatography showed two partially 
overlapping peaks after tag removal (data not shown). As shown in Figure 4A and C, 
there are two bands on the SDS-PAGE gel, and both were able to bind Fn (Fig. 4D); 
however, only the higher MW band exhibited Fg-binding activity (Fig. 4B) in the ligand 
blot analysis. The larger band migrated as an apparent molecular mass around 180 kDa 
(Fig. 4A), which was much greater than the calculated MW (105 kDa) for full-length 
FnBPA. This is expected, because FnBPA is composed of 11 repetitive disordered 
segments, and slower SDS-PAGE migration is a hallmark of an intrinsically disordered 
protein. 
* Part of the data reported in this chapter is reprinted and modified with permission from “Allosteric 
Regulation of Fibronectin/alpha5beta1 Interaction by Fibronectin-Binding MSCRAMMs” by Liang, X.; 
Garcia, B. L.; Visai, L.; Prabhakaran, S.; Meenan, N. A.; Potts, J. R.; Humphries, M. J.; Hook, M. PLoS One 
2016, 11 (7), e0159118. CC by PloS, copyright 2016; and from “Amino acid polymorphisms in the 
fibronectin-binding repeats of fibronectin-binding protein A affect bond strength and fibronectin 
conformation” by Casillas-Ituarte NN, Cruz CHB, Lins RD, DiBartola AC, Howard J, Liang X, Höök M, 
Viana IFT, Sierra-Hernández MR, Lower SK. J Biol Chem. 2017, 292(21):8797-8810. doi: 10.1074/jbc. 
M117. 786012. Copyright 2017. 
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Figure 4. Far-Western ligand blot of recombinant FnBPA with Fg and Fn 
(A and C) Purified and tag-removed recombinant FnBPA are separated and visualized on 
an SDS-PAGE gel with Coomassie staining. Calculated MW of full-length FnBPA 
protein is 105 kDa. (B) Fg ligand blot was probed with anti-Fg pAb. FnBPA-N2N3 (Fg-
binding domain) was included as a positive control. (D) Fn ligand blot was probed with 
anti-Fn pAb. One high-affinity Fn-binding repeat FnBPA-9 (GST-tagged) was used as a 
positive control. 
 
 
This initial characterization indicates that the full-length FnBPA is prone to 
degradation, resulting in reduced Fg binding. The degradation of FnBPA must occur 
from the N-terminus since the purification happens through the C-terminal His-tag. To 
generate intact, full-length, and stable truncations of FnBPA, I improved the initial 
expression and purification strategy by adding a 2xStrepII-tag and a TEV protease 
cleavable site to the N-terminus of the FnBPA gene to generate a double-tagged FnBPA 
construct (Fig. 5) for purification and characterization of full-length FnBPA (FnBPA38–
981 or FnBPAfl) and different truncations. 
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Figure 5. Construct designed for double-tagged FnBPA expression and purification 
Sequence encoding FnBPA was cloned into the BamHI/NheI multiple cloning sites of 
the modified pET15b vector. Construct utilizes N-terminal twin Strep-tag II and an 
expression tag at the C-terminus that encodes for GFP, followed by the 6xHis tag. The 
tags at both ends can be removed with TEV protease cleavage sites. Five constructs used 
for this study are shown. 
 
 
 
3.2. Generation of FnBPA biosensor for SPR-binding study 
Adhesion reactions depend on the conformation of the surface molecule and 
whether a system is static or dynamic.70-72 To characterize the interaction that is more 
relevant to physiological conditions, I used the SPR-based Biacore platform to create 
sensor surfaces that mimic the surface orientations of the molecules studied, for example, 
FnBPA on the bacterial surface and the integrin receptor on host cell surface. 
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Figure 6 shows the schematic of the SPR sensor chips and capture strategies. This 
approach generates a directed structural orientation of FnBPA that is tethered to the 
surface, potentially offering optimal site exposure and flexibility. Taking advantage of 
the double tags, N-terminal capturing can provide additional binding information and 
validation of the assay system. 
 
 
 
Figure 6. Schematic of the SPR sensor chips and capture strategies 
Biacore sensor chip CM5 was used to capture antibodies. All chips have a gold layer 
coated with a carboxymethylated dextran matrix and use amine coupling to covalently 
link (A) an anti-histidine tag antibody that can capture a C-terminal His-tagged FnBPA 
protein, or (B) an anti-Strep-tag II antibody that can capture an N-terminal Strep-tag II-
linked FnBPA protein to the chip surface. This approach generates a directed structural 
orientation of FnBPA that is tethered to the surface, offering optimal site exposure and 
flexibility. 
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3.3. Strong binding of Fg, Fn, and plasma to surface-anchored FnBPA 
The interaction between Fg and FnBPA has been studied by different groups 
using such techniques as ELISA, fluorescence polarization, ITC, and SPR.7, 28 The 
reported affinities between FnBPA truncates and FgγC peptide or immobilized Fg were 
from 1 to 10 µM. In this study, when full-length FnBPA was tethered to sensor chip 
surface, it reacted rapidly and tightly with the host ligands. As shown in Fig. 7, Fg binds 
to FnBPA with a KD value of 10 nM (Fig. 7A), which is more than 100-fold stronger than 
previous values, while KD value for Fn binding of 0.4 nM (Fig. 7B) was similar to the 
previously determined KD using ITC and SPR methods. Interestingly, when the FnBPA 
surface was exposed to human blood plasma, the plasma–FnBPA interaction (Fig. 7C) 
was tighter, based on the slower observed off-rate (smaller kd value). Although the ka and 
KD values for plasma binding could not be determined because the concentration of the 
binding component was unknown, comparing the dissociation phase (kd or complex 
halftime, which is concentration independent) after complexation (Fig. 7D) indicates that 
plasma strongly reacts with FnBPA surface and forms much more stable complex than 
Fn or Fg alone. It is unclear why there is such a huge difference in the complex halftime 
values measured for plasma with Fn and Fg (5095 s, 577 s, and 164 s, respectively) in 
Fig. 7D. While Fg dissociates rapidly, the plasma component did not dissociate from 
FnBPA surface. 
On the same FnBPA surface, the occupancy of plasma binding is ~ 800 RU (Fig. 
7C), which is much higher than the combined occupancy from Fg (~ 50 RU, Fig. 7A) 
and Fn (~ 180 RU, Fig. 7B). This is expected because, within a single FnBPA molecule, 
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there are more than six Fn binding sites and one Fg binding site. Multivalent Fn binding 
is clear with the intact and compact Fn in the plasma compared to the purified Fn with an 
extended conformation (multiple steps and harsh conditions partially unfolded the Fn 
tertiary structure). Such an effect of Fn binding may also contribute to the observed 
stable plasma–FnBPA complex. 
 
 
 
 
Figure 7. SPR binding analyses of Fg, Fn, and plasma binding to FnBPA surface 
FnBPAfl was captured by the SPR sensor chip which had immobilized anti-His mAb. (A) 
Fg at 10, 30, 90, and 270 nM; (B) Fn at 1, 3, 9, and 27 nM; and (C) human blood plasma 
at 0.37%, 1.1%, 3.3%, 10%, and 50% was injected onto the FnBPAfl surface. SPR 
response curves are shown with colored lines: lowest curve corresponds to the lowest 
concentration of sample injected. Kinetic analyses were performed by fitting SPR 
response curves to a 1:1 Langmuir binding model (fit lines are shown in black). ka and 
KD values for plasma binding could not be determined due to unknown ligand 
concentration. (D) Complex halftime (t½ = ln2/kd) was determined based on the 
dissociation constant of the complex and used as a signature of FnBPA:ligand(s) 
complex for comparison. 
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3.4. Fg and Fn in plasma simultaneously bind FnBPA 
The previous study of Fg binding to a FnBPA construct (FnBPA189–550) 
containing adjacent Fg- and Fn-binding sites revealed that Fg binding is negatively 
regulated by the binding of Fn. To evaluate whether such regulation also occurs in full-
length FnBPA, the plasma–FnBPA interaction was characterized in more detail. As 
shown in Fig 8, when the FnBPA sensor surface was exposed to the plasma, both Fg and 
Fn can bind simultaneously. The half maximum binding of plasma to FnBPAfl was 
estimated to be 15% (Fig 8A). The expected Rmax for the 1:1 interaction of Fn: FnBPAfl 
was 150 RU, while that for Fg: FnBPAfl was 100 RU. Based on the experimental Rmax 
value of 980 RU, if Fn and Fg were the only components that bound to FnBPA, the 
stoichiometry calculated as Fg:FnBPAfl = 6:1 and Fg:FnBPAfl = 1:1. This suggests that 
all six high-affinity Fn-binding sites in FnBPAfl can be saturated with Fn, and Fg can still 
bind to FnBPAfl. Figure 8B shows that molecules in the blood plasma binding to FnBPAfl 
resulted in a total response of ~ 780 RU. This plasma component could be recognized by 
anti-Fg (~300 RU) and anti-Fn (~1800 RU) at a recognition ratio of 6:1 (anti-Fn:anti-Fg). 
This reveals that six times more Fn than Fg can be recognized in the plasma by FnBPAfl, 
implying that all the six high-affinity Fn-binding sites are occupied by the compact Fn 
molecule, without steric hindrance effects and with such high Fn occupancy Fg can still 
bind. 
3.5. Fg binds tightly to the FnBPA surface at additional contact sites 
There is a large discrepancy in FnBPA–Fg binding affinity measurements 
between those previously reported (micromolar range) and the SPR results from this 
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Figure 8. Characterization of plasma–FnBPA interaction 
FnBPAfl was captured by the anti-His antibody on the Biacore chip and (A) serially 
diluted plasma was injected onto the FnBPAfl surface (~30 RU). (B) Plasma (10%) was 
injected onto FnBPAfl, followed by anti-Fg and anti-Fn polyclonal antibodies. 
 
 
 
study (~ 10 nM). Some possible explanations are: (1) the amine coupling of Fg or FgD in 
the previous studies7, 28 could potentially destroy the conformation of the Fg or FgD 
molecules. (2) The slower off-rate observed in Figure 7A, compared to the previously 
shown very fast off-rate (too fast to detect any kinetics, based on the sensorgrams shown 
in the papers28), indicates that complex formation may involve another region of Fg in 
addition to the γ-chain peptide. To address these questions, FgD-dimers, whose FnBPA 
binding site is blocked or inactivated by γ chain cross-linking (Fig. 3) and directly 
immobilized Fg and FgD, were used for the SPR assay. As shown in Figure 8, amine 
coupled Fg molecules (Fig. 9A to C) bind weaker (micromolar affinities) compared to 
soluble Fg molecules (Fig. 9D to F), with low nano-molar affinities. FgD and FgD dimer 
(FgγC inactive form) show similar binding strength to FnBPA, indicating that there is an 
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alternative FnBPA binding site in FgD, in addition to that on the γ-chain. When the 
FnBPAfl surface was exposed to Fg (Fig. 9D), stronger binding was observed (KD = 10 
nM) compared to FgD (KD = 86 nM), suggesting that there may be alternative binding 
site or conformation in Fg that is not present in FgD. Data from these SPR binding 
analyses are summarized in Table 4. 
 
 
 
 
Figure 9. SPR analyses of the interaction between Fg and FnBPA 
Analyte solution at indicated concentration was injected onto the ligand surface. (A–C) 
Host ligand was directly immobilized on the sensor chip. (D–F) FnBPAfl was captured 
on the SPR sensor chip with immobilized anti-His mAb. SPR response curves are shown 
with colored lines; lower curve corresponds to the lower sample. Kinetic analyses were 
performed by fitting SPR response curves to a 1:1 Langmuir binding model (fitted lines 
are shown in black). SPR experiments for other FnBPA proteins were done in the same 
way. KD and kinetic values are summarized in Table 4. FgD dimer binding was analyzed 
using the single-cycle kinetics method. 
 
 
 
3.6. Thrombin cleaves FnBPA and alters Fg-binding activity 
It was previously shown that proteolytic removal of N1 subdomain by thrombin 
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Table 4. Summary of the kinetic parameters for interactions from SPR 
Analyte 
solution 
Ligand 
surface 
  KD 
 
ka 
 
kd 
 
t1/2 
(s) 
Reference 
       
 Amine coupled (nM) (×106 M-1s-1) (×10–3 s-1)   
Fn FnBPA189–550 0.359 ± 0.001 ND ND  Stemberk28 
FnNTD FnBPA189–550 0.393 ± 0.002 ND ND  Stemberk28 
       
 His-tag Captured (nM) (×106 M-1s-1) (×10–3 s-1)   
Plasma FnBPAfl ND ND 0.136 5095 This work 
Fn FnBPAfl 0.321 ± 0.066 3.00 ± 0.20 1.08 ± 0.18 642 This work 
FnNTD FnBPAfl 0.263 ± 0.027 3.03 ± 0.42 0.80 ± 0.14 866 This work 
Fn FnBPA38–800 0.714 ± 0.146 1.70 ± 0.41 1.18 ± 0.06  587 This work 
Fn FnBPA38–672 0.639 ± 0.057 2.66 ± 0.46 1.58 ± 0.05 439 This work 
Fn FnBPA38–550 0.277 ± 0.042 4.04 ± 0.04 1.12 ± 0.01 619 This work 
FnNTD FnBPA38–550 0.260 ± 0.054 7.73 ± 1.64 1.95 ± 0.04 355 This work 
Fn FnBPA38–511 NB    This work 
       
 Amine coupled (nM) (×104 M-1s-1) (×10–3 s-1)   
FnBPA37–605 Fg 11,000 ±1200 ND ND  Wann7 
FnBPA189–
511 
FgD 1500 ± 100 ND ND  Stemberk28 
FnBPA189–
550 
FgD 1500 ± 100 ND ND  Stemberk28 
FnBPAfl Fg 725 ± 74 3.81 ± 0.39 27.5 ± 0.02 25 This work 
FnBPAfl FgD 1180 ± 165 2.32 ± 0.21 27.2 ± 1.32 25 This work 
FnBPAfl FgD dimer 1610 ± 511 0.52 ± 0.20 7.78 ± 0.02 89 This work 
FnBPA38–550 Fg 605 ± 29 3.89 ± 0.19 23.5 ± 0.00 29 This work 
FnBPA38–550 FgD 939 ± 40 2.21 ± 0.09 20.7 ± 0.00 33 This work 
FnBPA38–511 Fg 1420 ± 207 1.21 ± 0.55 17.1 ± 1.68 41 This work 
       
 His-tag Captured (nM) (×106 M-1s-1) (×10–3 s-1)   
Fg FnBPAfl 15.7 ± 5.6 24.2 ± 13.3 3.45 ± 0.75 201 This work 
FgD FnBPAfl 71.6 ± 20.0 23.7 ± 12.6 15.7 ± 4.26 44 This work 
FgD dimer FnBPAfl  163 0.339 0.553 1253 This work 
Fg FnBPA38–800 27.3 ± 1.8 10.4 ± 3.6 2.58 ± 1.47 269 This work 
Fg FnBPA38–672 22.3 ± 8.1 13.0 ± 3.7 2.70 ± 0.19 257 This work 
Fg FnBPA38–550 20.2 ± 7.6 18.6 ± 2.0 3.67 ± 1.13 189 This work 
FgD FnBPA38–550 375 ± 151 2.16 ± 0.6 7.63 ± 0.86 91 This work 
Fg FnBPA38–511 1030 ± 20 ND ND  This work 
       
FnBPAfl: full-length FnBPA or FnBPA38–981; ND: not determined; NB: no binding detected 
  
 
did not affect fibrinogen binding or biofilm formation.30 However, this study used an 
engineered S. aureus strain that harbored multiple copies of a shuttle plasmid carrying 
the fnbpA gene, and bacteria were grown in broth supplemented with thrombin. The size 
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of the cleaved product was estimated by SDS-PAGE of the surface-extracted FnBPA. In 
such an assay system, thrombin cleavage could be incomplete, and high expression of 
FnBPA within the strain and surface avidity could still allow bacteria to attach to the Fg-
coated plate. In this study, I used analytic methods with purified recombinant proteins as 
the substrate and re-purified the thrombin cut product for functional characterization. As 
shown in Fig. 10, thrombin digested full-length FnBPA into two fragments (Fig. 10A), 
and each appeared to have a higher than expected molecular mass (90,842 and 13,938 
Da), suggesting the presence of a disordered segment in the fragments. The thrombin 
treated full-length FnBPA, after gel filtration separation, the large protein peak was 
subjected to electrospray native mass spectrometry analysis (Fig. 10B). The mass of 
104,900 correlates to the full-length FnBPA, and the mass of 90,880 corresponds to 
FnBPA166–981 after thrombin cuts at Arg165. 
The activity of the thrombin-treated FnBPA surface was analyzed using SPR. The 
double-tagged FnBPA was first treated with thrombin and then captured on an anti-His 
sensor chip (the capturing step is actually a purification step). As shown in Fig. 10C and 
D, Fg binding was significantly reduced for FnBPA cut with thrombin, while Fn binding 
was unchanged. 
3.7. FnBPA38–550 is the minimal fully active Fg-binding domain 
The additional contact in Fg and strong Fg–FnBPA interaction raised the 
possibility that FnBPA may also require a specific conformation other than the 
previously identified N2N3 cleft region. Following this line of investigation, I isolated 
and characterized a series of FnBPA truncates to identify the minimal structure or 
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Figure 10. Thrombin cuts full-length FnBPA and alters Fg binding 
(A) SDS-PAGE gel indicates FnBPA can be processed by human thrombin proteinase. 1, 
Marker, 2, thrombin-treated FnBPA, and 3, untreated FnBPA. (B) Electrospray native 
mass spectrometry of purified FnBPA. Mass of 104,900 correlates to full-length FnBPA, 
and mass of 90,880 corresponds to FnBPA166–981 after thrombin cuts at Arg165. (C) Fg at 
270 nm and (D) Fn at 9 nm were injected onto the FnBPA surface (full-length FnBPA or 
FnBPA166–981 captured with anti-His mAb). The binding response was adjusted to 
represent the same amount of FnBPA captured. 
 
 
 
domain required for Fg binding, using the same SPR His-tag capturing approach. The 
binding data are listed in Table 4 and show that the C-terminal truncations FnBPA38–800, 
FnBPA38–672, and FnBPA38–550 bind to Fg with similar affinity (KD values of 27, 22 and 
20 nM, respectively) values as the full-length FnBPA (KD ≈ 16 nM). Further truncation 
(FnBPA38–511) resulted in dramatically reduced affinity (KD ≈ 1030 nM), about a 50-fold 
reduction. When the N1 region was removed by thrombin, the N-terminal truncated 
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FnBPA (FnBPA166–981) showed impaired Fg binding (Fig. 10). Together, these data 
suggest that FnBPA38–550 is the minimal fully active Fg-binding domain. It also confirms 
the original assignment of the Fg-binding domain (Fig. 1). 
3.8. Characterization of FnBPA conformation in solution 
Figure 11 shows the CD spectra of FnBPA proteins after tag removal. The CD 
spectrum indicates that FnBPA189–511, which includes the N2N3 domain of FnBPA, 
mainly consists of β-sheets. Comparing the CD spectra of all proteins containing the A 
domain (FnBPA38–981, 38–800, 38–672, 38–550, and 38–511) (Fig. 11A), a slightly stronger negative 
peak at 220 nm for FnBPA38–550 suggests that it contains more β-strands than FnBPA38–
511 and other constructs. The deduced spectral regions for FnBR all exhibit a random coil 
structure, except the deducted 511–550 (or FnBPA-1) region. FnBPA-1 is the first Fn-
binding repeat and predicted to be disordered by itself, but the deduced structure (Fig. 
11B) indicated that it is partially a β-strand when it is connected with the structured A 
domain as a single protein. The negative peak near 200 nm is characteristic of random 
coils and can be seen in proteins that harbor disordered FnBR (FnBPA38–981, 38–800, and 38–
672), with more disordered repeats showing a stronger negative signal. 
Conformational changes of proteins under various external influences (pH, ionic 
strength, temperature, etc.) can be investigated using intrinsic fluorescence, which is 
generated by aromatic amino acid residues (tryptophan [Trp], tyrosine [Tyr] and 
phenylalanine [Phe]).73 Among them, Trp is most ideal fluorophore because of its high 
quantum yield in proteins and the sensitivity of fluorescence to the local environment. 
For instance, when a ligand binds to a protein in the vicinity of a Trp residue, changes in 
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fluorescence intensity may occur. Moreover, the maximum wavelength of the 
fluorescence spectrum of Trp strongly depends on the polarity of its microenvironment. 
 
 
 
Figure 11. CD spectra of FnBPA proteins 
(A) Secondary structure of recombinant FnBPA proteins (tag-free) in 10% PBS 
examined using CD spectroscopy. (B) Spectrum of the A domain (38–511) was 
subtracted from those of proteins containing FnBR (FnBPA38–550, 38–672, 38–800, and 38–981), 
and the deduced spectra reflect the secondary structure of the FnBR region (511–550, 
511–672, 511–800, and 511–981) in each protein. 
 
 
 
 FnBPA contains only one Trp residue, at position 494 (Fig. 1) in the G’ strand in 
the N3 subdomain; there are 34 Tyr residues distributed throughout the protein (Table 5). 
G’ strand is directly involved in the β-zipper interaction with the FgγC peptide, as shown 
in the crystal structure of the complex.28 Figure 12 shows the fluorescence emission 
spectra of different FnBPA proteins (each containing the N1N2N3 domain) when excited 
at 280 nm (targeting Tyr) or 295 nm (targeting Trp). When the protein solution was 
excited at 295 nm, the maximum Trp fluorescence emission wavelength did not change 
(~340 nm, Figure 12B), indicating that Trp was partially buried in all proteins examined. 
Since there is only 1 Trp residue in the entire protein, when the protein concentration was 
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kept at 1 µM, the Trp concentration was also at 1 µM concentration. Comparing the 
emission spectra indicated a significantly higher quantum yield for longer constructs 
FnBPA38–981 and FnBPA38–550 than for FnBPA38–511 (Fig. 12 A and B). This difference is 
not due to structural changes because the maximum wavelength remained the same; it is 
due to the contribution of the excitation energy being transferred from additional Tyr 
residues (in FnBR region) nearby (Table 5). It is possible that a non-linear structure 
 
 
 
Figure 12. Intrinsic fluorescence spectra of FnBPA proteins 
(A and B) Comparison of intrinsic fluorescence spectra of FnBPA38–981, FnBPA38–550, 
and FnBPA38–511 (1 µM protein in 50 mM Tris and 150 mM NaCl, pH 7.5) excited at 280 
or 295 nm. (C and D) Intrinsic fluorescence spectra of 1 µM FnBPA and emission ratio 
comparison of Trp (335 nm) and Tyr (310 nm) under 5 conditions: 1) 50 mM sodium 
phosphate (pH 6.2), 2) 50 mM Tris (pH 7.5), and 3) 50 mM sodium borate (pH 8.5), all 
contain 150 mM NaCl, and 4) 50 mM Tris pH 7.5, 50 mM NaCl (low salt) and 5) 50 mM 
Tris pH 7.5, 500 mM NaCl (high salt). 
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existed in the full-length FnBPA, in which the C-terminal disordered region was close to 
the structured A domain at the N-terminus. The larger fluorescence difference between 
FnBPA38–550 and FnBPA38–511 (Figure 12B) indicates that FnBPA-1 may closely 
associate with the N3 domain to form a compact structure. It also suggests that the 
original A domain assignment, which included FnBPA-1 as a subdomain, is more 
relevant. Furthermore, the conformational fluctuation of full-length FnBPA was 
observed in different pH and ionic strength solutions (Figure 12C and D); low pH (pH 
6.2) had a more dramatic effect on the tertiary structure of FnBPA (Figure 12C). 
 
Table 5. FnBPA amino acid composition and properties 
Region Residues # of 
aa 
pI # of 
Tyr 
Tyr % 
(Tyr total=34) 
N1 38–194 157 4.66 1 2.9 % 
N2 195–338 144 5.36 4 11.7 % 
N3 339–511 173 6.34 14 41.1 % 
FnBPA-1 512–550 39 4.25 3 8.8 % 
FnBPA-2 551–580 30 3.54 3 8.8 % 
FnBPA-3 581–609 29 3.94 2 5.9 % 
FnBPA-4 610–636 27 4.24 1 2.9 % 
FnBPA-5 637–672 36 4.12 0 0 
FnBPA-6 673–703 31 3.63 1 2.9 % 
FnBPA-7 704–732 29 4.66 1 2.9 % 
FnBPA-8 733–762 30 4.05 1 2.9 % 
FnBPA-9 763–800 38 4.35 1 2.9 % 
FnBPA-10 801–838 38 5.01 1 2.9 % 
FnBPA-11 839–874 36 3.89 1 2.9 % 
PR 875–951 107 4.84 0 0 
FnBPA38–511 38–511 474 5.13 19 55 % 
FnBPA38–550 38–550 513 4.98 22 65 % 
FnBPA551–981 551–981 454 4.23 12 35 % 
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3.9. Fg-binding activity of FnBPA is affected by ionic strength and pH 
 The interaction between Fg and FnBPA is presumably driven by electrostatic 
interactions. As shown in Figure 13A and B, the KD values are 15, 22, 125, and 197 nM 
for binding under 50, 150, 300, and 600 nM NaCl, respectively. This suggests that Fg-
FnBPA interaction is weaker when ionic strength increases. The difference in binding 
affinity is primarily due to a faster on-rate in lower salt concentrations (Fig. 13C). The 
pH difference (ranged from 7.0 to 8.5) did not seem to affect binding affinity (Fig. 13F).  
 
 
 
Figure 13. Binding of Fg to FnBPA under different conditions with SPR 
Fg in 50 mM Tris (pH 7.5) and different concentrations of NaCl (50, 150, 300, or 600 
mM) was injected (250 nM Fg was shown) onto (A) anti-His or (B) anti-Strep captured 
FnBPAfl. (C) Binding kinetics were measured for each condition and compared in on-off 
rate map. Fg in four different pH buffer systems containing 150 mM NaCl (50 mM 
KHPO4 pH 6.2, 50 mM Tris pH 7.0, 50 mM Tris pH 8.0, and 50 mM borate pH 8.5) was 
injected (250 nM Fg shown) onto FnBPAfl captured by (D) anti-His or (E) anti-Strep. (E) 
Binding kinetics were measured for each condition and compared in on-off rate map. All 
buffers contained 0.02% Tween-20. 
 45 
 
However, at pH 6.2, Fg was not able to bind C-terminally captured FnBPA (Fig. 13D), 
while the N-terminally captured FnBPA was still able to bind Fg (Fig. 13E). 
 
Table 6. Thermodynamic parameters for the interactions (25 °C ) by ITC and SPR 
Interaction   KD 
 
  ΔG 
(kJ/mol) 
ΔH 
(kJ/mol) 
 -TΔS 
(kJ/mol) 
 n Met
hod 
Reference 
 
FnBPA189–550:Fg 
 (µM) 
1.1 ± 0.1 
  
  -33.8 
 
-25.5 ±0.0 
 
  -8.3 
 
2.11 
 
ITC 
 
Stemberk28 
FnBPA38–550:Fg 0.23 ± 0.08   -37.9  -28.3 ±0.4   -9.5 1.91 ITC This work 
FnBPA38–550:Fg 0.66 ± 0.19   -35 -37 ± 1.7   2.0  SPR This work 
FnBPAfl : Fg 1.23 ± 0.16   -34 -19 ± 1.3   -15  SPR This work 
FnBPA38–550:FgD 0.86 ± 0.17   -35 -24 ± 1.2   -11  SPR This work 
FnBPAfl:FgD 1.04 ± 0.15   -34 -22 ± 1.6   -12  SPR This work 
   (nM)       
FnBPA189–550:FnNTD 0.7 ± 0.2   -52.4 -150 ±1.2   97.3 0.89 ITC Stemberk28 
FnBPAfl:Fn 
FnBPA-1:FnNTD 
FnBPA-4:FnNTD 
FnBPA-5:FnNTD 
FnBPA-8:FnNTD 
FnBPA-9:FnNTD 
FnBPA-10:FnNTD 
FnBPA-11:FnNTD 
 
0.9 ± 0.7 
4.8 ± 0.6 
10.5 ± 0.9 
44.2 ± 9.7 
~ 3000 
7.9 ± 0.4 
19.5 ± 1.1 
<1.0 
  -51.5 -986 ± 49 
-108 
-120 
-71 
-81 
-117 
-102 
-118 
935 
61 
75 
29 
50 
71 
58 
- 
0.15 
0.84 
0.37 
0.91 
0.76 
0.99 
0.98 
1.01 
ITC 
ITC 
ITC 
ITC 
ITC 
ITC 
ITC 
ITC 
This work 
Meenan40 
Meenan40 
Meenan40 
Meenan40 
Meenan40 
Meenan40 
Meenan40 
 
 
 
The observation suggested that the folding of the FnBPA C-terminus affects Fg 
binding at the N-terminus, providing experimental evidence to support the folded-back 
conformation of active FnBPA. Since ionic strength does not change the local N2N3 
conformation, as indicated by the intrinsic tryptophan fluorescence of FnBPA (Fig. 12C 
and D), the change in the binding activity might be caused by the region outside the 
N2N3 domain. Furthermore, the pH effect on FnBPA conformation is most obvious at 
pH 6.2, as demonstrated by the fluorescence (Fig. 12C) when Tyr residues outside the 
N2N3 region were excited. These results further support a model where the N1 and C-
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terminus of FnBPA form the folded-back structure. The conditions tested did not affect 
Fn binding to FnBPA (data not shown). 
3.10. Thermodynamics of FnBPA binding to Fg and Fn 
The binding energies of FnBPA interactions with Fg and Fn were directly 
measured by ITC (Fig. 14) or determined using SPR with van ‘t Hoff analyses (Fig. 15). 
By comparing the ITC data (Table 6) for the interaction of Fg and FnBPA38–550 and Fg 
and FnBPA189–550, a 5-fold stronger affinity (0.23 µM vs. 1.1 µM, respectively) for the 
longer construct was driven by a favorable extra enthalpy contribution of ~2.8 kJ/mol  
 
 
 
Figure 14. ITC experiment for FnBPA and host ligand interaction 
(A and C) Curves for each injection heat. (B and D) The estimated heat of binding (ΔH) 
as a function of molar ratio, and fitted curve calculated from integrated raw data using 
the One Set of Sites fitting model. Measured and deduced parameters are listed in Table 
6 and converted to kJ/mol. 
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(ΔH = -25.5 vs. -28.3 kJ/mol), as well as an extra entropy contribution of ~ 1.2 kJ/mol   
(-TΔS = -8.3 vs. -9.5 kJ/mol), suggesting that the N1 region (aa 38–189) is involved in 
direct binding driven by both enthalpic and entropic interactions. The stoichiometry of  
1.91:1 for the Fg:FnBPA38–550 interaction was consistent with the presence of two 
identical binding sites on intact dimeric Fg. 
 
 
Figure 15. SPR determination of binding thermodynamics 
Van ‘t Hoff plots generated for the binding of FnBPAfl to immobilized Fg and FgD, and 
FnBPA550 to Fg and FgD. KD values were obtained by SPR kinetic analysis at a series of 
temperatures (15, 20, 25, 30, 35, and 40 °C). The resulting plot of ln KD against 1/T is 
linear, with a slope of ΔH/R and an intercept on the y-axis of ΔS/R at standard 25 °C (R 
is the universal gas constant). Thermodynamics parameters derived from van ‘t Hoff 
analysis are listed in Table 6. 
 
 
 
Thermodynamics data derived from SPR measurements demonstrated a reduced 
enthalpy of binding (except for Fg and FnBPA38–550), but binding was still enthalpy 
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dominated. By comparing the same Fg-FnBPA38–550 interaction with ITC and SPR, the 3-
fold weaker affinity (KD = 0.23 vs. 0.66 µM) obtained from the SPR method was mainly 
due to an unfavorable entropic penalty (-TΔS = 0.8 kJ/mol), presumably arising from 
immobilization of Fg, which blocks the hydrophobic region from binding and restricts 
conformational freedom. This steric hindrance and lack of conformational flexibility for 
immobilized Fg and FgD is also a limiting factor for FnBPAfl binding, which might 
require an extended interface, evidenced by smaller binding enthalpy (ΔH = -19 and -22 
kJ/mol) and non-dominated entropy. 
ITC measurements upon the binding of FnBPA to Fn indicated that binding is 
completely driven by favorable enthalpic contributions and an unfavorable entropy 
signature that is expected, given that the disordered repeat region becomes structured 
upon binding (β-zipper mechanism). Full-length FnBPA is composed of seven 
measurable Fn-binding sites (FnBPA-1, 4, 5, 8, 9, 10, and 11) and six exhibits high 
affinity.40 FnBPA189–550 has only one Fn-binding site, FnBPA-1 (FnBPA511–550), in the 
protein. The KD values for FnNTD binding, determined with ITC measurements, were 
0.7 nM for FnBPA189–550 and 4.8 nM for FnBPA-1 peptide. These different KD values  
indicate that the presence of the N2N3 domain in FnBPA189–550 can stabilize the FnBPA–
Fn interaction by ~6-fold. This is supported by more favorable enthalpy (ΔH = -150 vs. -
108 kJ/mol), which could potentially strengthen the interaction. The greater entropic cost 
(ΔS = 97 vs. 61 kJ/mol) suggests that conformational rearrangement could extend to 
other regions of the protein. Applying an additional enthalpy contribution of -42 kJ/mol 
and an entropic penalty of 36 kJ/mol to the other five high-affinity Fn-binding repeats 
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(Table 6), the total ΔH will become -972 kJ/mol, and total ΔS will be 621 kJ/mol for 
FnNTD binding to longer a FnBPA protein that contains N2N3 and all repeats. 
Interestingly, the experimentally determined parameters for the FnBPAfl–Fn interaction 
are consistent with overall tight binding (KD value of 0.9 nM) and a dominant enthalpy 
contribution (ΔH = -986 kJ/mol), as well as stoichiometry of ~6:1 (n=0.15). The larger 
entropic term (-TΔS = 935 kJ/mol) indicates that other regions of the full-length proteins 
might be affected, for example, the N1 region in FnBPA of GBD region in Fn. 
3.11. Specificity of FnBPA ligand bindings 
To confirm the binding specificity between FnBPA and host ligands Fg/Fn, 
several inhibition assays were performed using SPR to exam the ability, efficacy, and 
interplay of soluble ligands inhibiting FnBPA binding to immobilized ligands. 
3.11.1. Inhibition of FnBPA binding to Fn surface 
Fn can interact with Fg at two binding sites on Fn. The primary high-affinity site 
is located at the FnNTD30k region (F4-F5 domains, the same region that FnBPA binds) 
,and the second binding site is cryptically located at the C-terminal Fib-2 region (Fig. 
2).51 For this reason and the possibility of Fn self-association, the ability of soluble Fg or 
Fn to inhibit FnBPA binding to Fn or the FnNTD30k surface could not be determined. 
3.11.2. Inhibition of FnBPA binding to Fg surface 
 Figure 16 shows that Fn did not inhibit or interfere with full-length FnBPA 
binding to immobilized Fg (Fig. 16A), demonstrating that Fn binding to FnBPA is 
independent of Fg binding. Both soluble Fg and FgD could inhibit FnBPA binding to 
immobilized Fg (Fig. 16B and C); the IC50 for inhibiting FnBPAfl binding to Fg was 0.21 
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Figure 16. Inhibition of FnBPA binding to Fg surface 
Dose-response for inhibition by different concentrations of (A) Fn, (B) Fg, (C) FgD, or 
(D) Fgγ peptide of 0.5 M FnBPAfl binding to immobilized Fg. The maximum (100%) 
response was FnBPAfl binding without any inhibitors (control). (E) FnBPAfl binding 
responses from A–D were plotted against inhibitor concentrations (dimer Fg and Fn 
concentrations were used) and fit to a four-parameter logistic function. Fg IC50 for 
inhibiting FnBPAfl binding to Fg was 0.21 µM, and the FgD IC50 was 0.85 µM. 
 
 
 
µM, and the FgD IC50 was 0.85 µM (Fig. 16E). The 4-fold less efficacy in inhibition 
suggests possible contact sites outside the FgD fragment in Fg. Interestingly, the FgγC 
peptide could not inhibit the Fg–FnBPA interaction under the tested conditions; instead, 
it enhanced FnBPA binding to the Fg surface (Fig. 16D and E). A possible explanation is 
that amine coupled Fg is a modified Fg surface that exposes another specific binding site 
for FnBPA. These data indicate that the Fg–FnBPA interaction is more complex than 
previously considered. 
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3.11.3. Specific engagement of FgγC requires FnBPA N1 domain 
 To address the unexpected effect observed in the inhibition assay on FnBPA, a 
protein fluorescence quenching experiment was used to study FnBPA–FgγC peptide 
binding in solution. Static quenching of tryptophan fluorescence of FnBPA after the 
addition of the FgγC peptide, which does not contain any aromatic residues, was 
analyzed according to the Ster–Volmer plot and modified Stern–Volmer plot.74 The data 
displayed in Figure 17 show that the quenching of FnBPA fluorescence by the addition 
of FgγC was only seen in N1 containing FnBPA proteins (A, B, D, and E) but not in  
FnBPA189–511 , which only has the N2N3 domains (C and F). The Stern–Volmer curves 
exhibit linearity (Fig. 17G), suggesting that the quenching process arises from binding 
between the tryptophan fluorophore and the quencher peptide. The linearity of the 
modified Stern–Volmer plots indicates static quenching (or binding) in the presence of 
an inaccessible population of fluorophores. The KD values are almost the same for both 
full-length FnBPA (KD =1.83 µM) and FnBPA38–511(KD =1.82 µM), which is consistent 
with a solution affinity of ~1.1 µM for the Fg–FnBPA189–550 interaction measured by 
ITC28 (Table 4). The lower accessibility of Trp in full-length FnBPA (48%) than 
FnBPA38–511 (68%) indicates that FnBR may be involved in the dynamic folding of the A 
domain. Since FnBPA has only one Trp residue in the protein, the end-point measured 
accessibility of 48–68% suggests possible equilibrium between cleft-occupied and cleft-
unoccupied conformations. The N1-dependent quenching events also suggest that N1 is 
involved in regulating cleft occupancy. No quenching in FnBPA189–511 does not mean 
that there is not binding between the protein and FgγC peptide (pair shown in the 
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Figure 17. Static quenching of tryptophan fluorescence in FnBPA by FgγC peptide 
(A–F) Fluorescence emission spectra of FnBPA proteins (1 µM), and quenching of the 
fluorescence when the FgγC peptide was titrated into protein solutions. Quenching of 
FnBPA tryptophan fluorescence by addition of FgγC peptide (which does not contain 
any aromatic residues) are only seen in N1 containing FnBPA proteins (A, B, D, and E), 
not in FnBPA189–511, which has only N2N3 domains (C and F). (G) Stern–Volmer curves 
(data from 295 nm excitation), where F0 and F are the fluorescence intensities at 335 nm 
in the absence and presence of FgγC peptide, respectively, exhibit linearity, suggesting 
that the quenching process arises from binding between the tryptophan fluorophore and 
the quencher peptide. (H) The linearity of the modified Stern–Volmer plots indicates 
static quenching (or binding) in the presence of an inaccessible population of 
fluorophores. Plots allow calculation of KD (slope/intercept) and percentage of 
tryptophan accessibility (100/intercept) for quenching: 48% for FnBPA38–981, and 68% 
for FnBPA38–511. 
 
 
complex structure28), rather it indicates that the binding did not result in a change of Trp 
fluorescence due to a lack of conformational change. 
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3.11.4. Inhibition of Fg and Fn binding to FnBPA surface   
FnBPA contains multiple binding sites for Fn interaction. To avoid complexity, 
the Fn inhibition assay was performed using an individual peptide of FnBR region. As 
shown in Figure 17, soluble FnBPA can inhibit Fg binding to the full-length FnBPA 
surface (Fig. 18A). The IC50 value of 424 nM (Fig. 18C) is not very compatible with the 
Fg–FnBPA affinity value (10 nM) determined in Figure 7A, suggesting that Fg prefers 
binding surface-anchored FnBPA, which has an optimal structural orientation. In 
contrast, soluble FnBPA could completely inhibit Fn binding to the full-length FnBPA 
surface (Fig. 18B). The IC50 value of 0.86 nM (Fig. 18C) was compatible with the 
affinity values measured for surface-anchored FnBPA (0.4 nM, Fig. 7B and Table 4), 
because FnBPA has multiple Fn-binding sites, and each site is unstructured for binding. 
 
 
 
Figure 18. Inhibition of Fg and Fn binding to FnBPA surface by soluble FnBPA 
Various concentrations of FnBPAfl were mixed with (A) 100 nM Fg and (B) 10 nM Fn 
and then injected onto the FnBPAfl sensor surface. (C) Fg and Fn binding responses from 
A and B were plotted against inhibitor FnBPAfl concentrations and fitted to a four-
parameter logistic function. FnBPAfl IC50 for inhibiting Fg binding to FnBPAfl was 424 
nM, and the IC50 for inhibition of Fn binding was 0.86 nM. 
  
 
 
 Although a FnBPA–Fn interaction is mediated by several high-affinity repeats in 
FnBPA, binding of Fn to full-length FnBPA was completely inhibited by the single 
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repeat FnBPA-9 (Fig. 19), suggesting that this repeat plays a major role in Fn binding. 
This result is consistent with previously reported results that FnBPA-9 is a hot spot for 
infection related polymorphisms;22-23 also, an epitope in FnBPA-9 is exposed on the 
surface of S. aureus, and it is an effective target for murine mAb (15E11), which can 
inhibit the attachment of S. aureus to surface-coated Fn.75 
 
 
 
 
Figure 19. Inhibition of Fn binding to FnBPA surface by synthetic FnBR peptide 
(A) Various concentrations of FnBPA-9 were mixed with 10 nM Fn and injected onto the 
high-density FnBPAfl sensor surface. (B) Fn binding responses plotted against inhibitor 
FnBPA-9 concentrations and fit to four-parameter logistic function. FnBPA-9 IC50 for 
inhibiting Fn binding to FnBPAfl was 13 nM. Synthetic peptide FnBPA-3 (repeat that 
binds weakly to Fn) was used as a negative control that did not interact with Fn. 
 
 
3.11.5. Inhibition of plasma adsorption to FnBPA surface 
To investigate whether the inhibition observed in the purified system is still 
applicable to the more biologically relevant system, human blood plasma was used for 
the SPR binding assay. In these assays, the co-injection command was used to inject two 
samples in direct succession, with no dissociation time or wash procedures after the first 
injection, enabling the blocking of the ligand surface to be monitored. 
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Figure 20. Blockage and inhibition of plasma adsorption to FnBPA surface 
(A and B) Using the co-injection command, inhibitor (Fn, Fg or buffer) was first injected 
over the FnBPAfl surface, immediately followed by injection of 10% blood plasma, with 
no dissociation time after the first injection. (C) Data in A and B (adsorbed plasma 
response at the dissociation) are plotted to show the effect of blockage. (D) Each 
recombinant FnBPA fragment at 10 nM was mixed with 3% plasma (final concentration) 
and injected onto the FnBPAfl surface. 
 
 
The results indicated that as the concentration of Fn increased to 81 nM, the 
FnBPA surface became saturated with Fn and could almost completely block plasma 
adsorption to FnBPA (Fig. 20A and C). Fg could weakly and partially block plasma 
adsorption to FnBPA (Fig. 20B and C), even at 9 µM (equivalent to Fg concentration in 
plasma). These data suggest that Fn is the major (~ 90%) component in plasma that 
adsorbs to the FnBPA surface, while Fg only counts for ~10%. These results are 
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consistent with the ratio of FnBPA-bound Fn vs. FnBPA-bound Fg from plasma using 
antibody detection (Fig. 8A). Premix plasma with truncated FnBPA that contained FnBR 
(FnBPA38–511 does not contain FnBR) could also effectively inhibit plasma binding to 
full-length FnBPA (Fig. 20D). This further supports that FnBPA38–550 is likely minimal 
fully functional ligand binding domain. 
3.12. Allosteric regulation of Fg and Fn binding to FnBPA 
The Fn and Fg binding sites on FnBPA do not overlap, and the data presented in 
Section 3.4 demonstrates that Fn and Fg can simultaneously bind to surface-anchored 
FnBPA. To investigate how these two ligands influence the binding of the other to 
FnBPA to form a ternary complex, an SPR assay was developed in which the α-His and 
α-Strep antibodies were immobilized on the same sensor chip to detect complex 
formation when double-tagged FnBPAfl (His-tag at the C-terminus and Strep-tag II at the 
N-terminus) was mixed with Fg and Fn. 
Figure 21 shows that Fn-bound FnBPA had more Fg bound than the un-liganded 
FnBPA; thus a bigger complex could be detected by α-His (Fig. 21A and C). However, 
this enhanced Fn-FnBPA–Fg complex could not be detected by α-Strep, which 
recognizes the N-terminus of FnBPA (Fig. 21B and C). This suggests that Fn binding 
may involve the N-terminal region by stabilizing the fold-back conformation for optimal 
Fg binding, thus, sterically blocking the N-terminal tag from recognized by the antibody. 
In contrast, Fg-bound FnBPA showed less Fn binding than Fg-free FnBPA (Fig. 21D and 
F), but when a threshold concentration of Fn (100 nM) was reached, Fg– FnBPA-Fn 
complex formation was enhanced. However, α-Strep could not detect this enhancement, 
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Figure 21. Complexation of FnBPA with Fg and Fn in solution detected by SPR 
In an SPR assay, immobilized α-His and α-Strep antibodies were used as a sensor surface 
to detect double-tagged FnBPAfl under different complex formation conditions. (A–C) 
100 nM of FnBPAfl was mixed with increasing concentrations of Fg in the absence (data 
not shown) or presence of a saturating amount of 200 nM Fn; the mixture was then 
injected onto antibodies immobilized on the same sensor chip. (D–F) 100 nM of FnBPAfl 
was mixed with increasing concentrations of Fn in the absence (data not shown) or 
presence of saturating Fg (400 nM). 
 
 
 
which further confirmed that the N-terminal region of FnBPA is involved in ligand 
binding. 
These findings demonstrated that Fn is a positive allosteric effector of FnBPA 
binding to Fg, and Fg binding negatively influenced FnBPA binding to Fn when Fn 
concentration was low. However, this negative effect could be overcome with a greater 
available concentration of Fn. This positive cooperativity of ligand binding can explain 
the more stable interaction of FnBPA with plasma than the individual Fg or Fn ligand 
alone (Fig. 7). 
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3.13. Tertiary structure of Fn is altered by FnBPA 
Although high-resolution crystal structures have been solved for some smaller Fn 
fragments, a complete structure for full-length Fn remains to be determined. To 
understand whether conformational changes are induced by individual FnBR of FnBPA, 
DLS, CD, and fluorescence spectroscopy were used to analyze the native Fn 
conformation in solution. 
3.13.1. DLS detection of extended conformation of Fn altered by FnBPA 
The hydrodynamic radii (Rh) of Fn in the presence or absence of the FnBPA Fn-
binding repeat FnBPA-10 was measured using DLS (Table 7). Fn adopted an extended 
conformation in the presence of high salt or heparin (Rh = 13.27 ± 0.15; 12.50 ± 0.29, 
respectively) compared to a more compact structure found in physiological buffer (Rh 
=10.20 ± 0.12). An addition of FnBPA-10 resulted in a significantly increased Rh (Rh = 
12.73 ± 0.69), suggesting that Fn adopts an extended structure upon binding to FnBPA. 
 
Table 7. Comparison of hydrodynamic radii of Fn under various conditions 
Fn treatments  Rh (nm) 
TBS 10.20 ± 0.12 
High salt 13.27 ± 0.15 
Heparin  12.50 ± 0.29 
FnBPA-10 12.73 ± 0.69 
 
Fn was maintained in TBS at a final concentration of 0.8 mg ml-1 (1.6 μM). Different treatments included 
an additional 350 mM NaCl (high salt), 15 µM of heparin, or FnBPA-10 peptide. Values are mean ± SE. 
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Figure 22. Near-UV CD and steady-state fluorescence spectra of Fn 
(A) CD spectra in the range 250–350 nm are shown for individual molecules or mixtures: 
Fn dimer (0.82 mg ml-1, 1.6 µM), FnBPA-10 (0.07 mg ml-1, 15 µM), and heparin (0.27 
mg ml-1, 15 µM). TBS (50 mM Tris, pH 7.4, and 150 mM NaCl) was used for all 
experiments. (B and C) When excited at 295 nm, intrinsic tryptophan fluorescence 
spectra were recorded for Fn (0.1 μM) in TBS, TBS with 1 M GdnHCl or 2 μM of 
FnBPA-10, and FnNTD (1.6 μM) with and without 16 μM of FnBPA-10. All 
concentrations are final. Spectra were corrected by subtracting buffer blanks. 
 
 
 
3.13.2. CD detection of partial unfolding of Fn by FnBPA 
Native Fn contains large numbers of aromatic residues in the type I and III domains, 
which exist in common hydrophobic environments and give rise to a signature near-UV CD 
spectrum that is characterized by two strong negative peaks centered at 291 and 299 nm, and 
a weaker negative peak at 282 nm (Fig. 22A).76-77 The binding of Fn by the 
glycosaminoglycan heparin has been shown to alter the tertiary structure of Fn, which can be 
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monitored by shifts in this signature spectrum.78 When Fn was incubated in the presence of 
FnBPA-10, the complex produces different spectra relative to native Fn (Fig. 22A). 
Interestingly, the similarity in the near-UV spectra for heparin-bound Fn when compared to 
FnBPA-10 bound Fn (Fig. 22A) was noted. Importantly, heparin and the FnBPA-10 peptide 
used in these experiments are intrinsically disordered polymers that do not contain a Trp 
residue and, therefore, lack near-UV optical activity. However, since FnNTD is engaged by 
FnBPA-10, such an interaction could potentially cause near-UV CD optical activity changes 
within the NTD domain. FnBPA-10 caused intrinsic Trp fluorescence quenching in Fn (Fig. 
22B) and FnNTD (Fig. 22C), suggesting that Trp environments in the NTD are affected by 
binding and may partially contribute to the near-UV CD changes in Fn. 
3.13.3. FRET detection of partially unfolded Fn by FnBPA 
To learn whether FnBPA causes allosteric changes in Fn upon binding and to 
confirm apparent conformational changes in solution Fn indicated by CD, a FRET-based 
approach was employed. To this end, Fn was site-specifically labeled by conjugating an 
acceptor fluorophore to free cysteine residues using a technique previously described.69 
Native Fn contains only two free cysteines (four per dimer molecule), and these are 
found in the C-terminally positioned 7FnIII and 15FnIII modules79 (denoted in Fig. 2). 
When Fn is denatured by introducing increasing amounts of GdnHCl (Fig. 23A and B) or 
increasing the ionic strength (Fig. 23C), the distance between the amine coupled donor 
fluorophores and cysteine coupled acceptor fluorophores increased, and the acceptor 
fluorescence peak was diminished. There was no FRET observed between adjacent or 
denatured Fn molecules (Fig. 23D). To determine whether the FnBPA-induced structural 
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changes measured by CD and DLS involve Fn domains outside of the FnBPA binding 
site, spectra were then collected in the presence of various concentrations of FnBPA-10 
(Fig. 23F) GST fusion proteins. These experiments showed a clear dose-dependent loss 
of the acceptor peak signal for FnBPA-bound Fn. Importantly, an identical effect was 
observed when a 36-amino-acid peptide lacking the GST fusion and corresponding to the 
high-affinity FnBPA repeat FnBPA-5 was used (Fig. 23G). GST alone or a GST fusion  
 
 
Figure 23. FRET of Fn 
Fluorescence emission spectra of Fn-donor or Fn-acceptor (50 nM in 10 mM Tris, pH 
7.4, 150 mM NaCl) were collected with excitation at 493 nm (A) in the presence or 
absence of denaturant (GdnHCl). (B) Accompanying acceptor/donor peak ratio as a 
function of denaturant concentration. Fn-donor or Fn-acceptor fluorescence changes (C) 
under different ionic strengths and (E and F) in the presence of different concentrations 
of GST-FnBPA-10 or FnBPA-5 peptide, respectively. (G) Acceptor/donor peak ratio vs. 
concentration (0, 1, 5, 20, 50, or 200 nM) of protein or peptide added. Spectra were 
normalized to the donor emission peak at 522 nm such that changes in energy transfer 
were reflected only by changes in the acceptor peak at 570 nm. (D) Control experiments 
were conducted by mixing 50 nM of donor-labeled Fn (Fndonor) with 50 nM of acceptor-
labeled Fn (Fnacceptor) in TBS or 2 M GdnHCl. 
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to the low-affinity FnBPA repeat FnBPA-3 exhibited no effect in this assay system (Fig. 
23H). Taken together, the DLS, CD, and fluorescence-based assays indicated that 
FnBPA profoundly modifies the native solution structure of Fn by promoting an 
extended Fn conformation that results in the large-scale rearrangement of Fn domains at 
sites distant from the FnBPA binding site. 
3.14. Fn recognition of the α5β1 integrin enhanced by FnBPA 
Fn serves as a primary ECM substrate for several adhesion molecules, including 
the major Fn cell surface receptor, α5β1 integrin.42 Whether conformational changes 
induced by binding FnBPA, as shown in Fig. 22–23 and Table 7, resulting in modified 
Fn–integrin interactions were investigated. To more directly test this, an SPR-based 
system was developed to study the effects of FnBPA on recognition of the α5β1 integrin 
by Fn. 
3.14.1. Validation of SPR-based assay for integrin binding analysis 
In this assay system, a recombinant α5β1-Fc fusion protein representing the 
minimal functional unit of the integrin67 was immobilized on the surface of a Biacore 
CM5 chip. Fn interacts with the α5β1 biosensor, and binding is enhanced by Mn2+ (Fig. 
24A), as previously reported.67 Further validation of this experimental approach was 
performed using Fn fragments, including the cell-binding domain (FnCBD) possessing 
the canonical α5β1-binding “RGD” and synergy sites80-81 (Fig. 2). As expected, the 
FnCBD fragment exhibited a dose-dependent interaction with α5β1, while the FnNTD 
fragment lacking the integrin interaction domains failed to bind the integrin (Fig. 24B 
and C). 
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Figure 24. SPR analyses of Fn–α5β1 interaction 
The α5β1 biosensor was validated by demonstrating metal ion dependence and domain 
specificity: (A) Fn (250 nM) was injected over the immobilized α5β1 surface in the 
presence of 1 mM MnCl2 (solid line) or 3 mM EDTA (dashed line). (B) Response 
curves for a two-fold linear dilution series of FnCBD over immobilized α5β1 are shown. 
(C) Comparison of Fn (250 nM, solid line) and FnNTD fragment lacking the canonical 
integrin-binding RGD-motif (500 nM, dashed line). 
 
 
3.14.2. SPR analysis revealed enhanced Fn-α5β1 interaction by FnBPA 
Using this SPR approach, a moderate affinity of ~1 µM for Fn-α5β1 (Fig. 25A and 
C) was measured, which is in good agreement with affinities reported for fibroblast cell 
interactions with plasma Fn.82 To understand whether FnBPA binding to Fn affects the 
Fn–α5β1 interaction, mixtures of FnBPA-10/Fn (fixed FnBPA + varied Fn 
concentrations) were injected over the immobilized α5β1 integrin. A remarkable 
enhancement of the binding response was observed for FnBPA-bound Fn relative to 
native Fn (Fig. 25 B). To obtain a quantitative measure of the increase in affinity, kinetic 
parameters were obtained by fitting SPR response curves to a bivalent analyte binding 
model. This model was selected based on closeness of fit (χ2≈1, Table 1) and the 
assumption that dimeric Fn contributes one identical α5β1 binding site per subunit. The 
analysis for each interaction revealed that the approximately four-fold increase in 
apparent affinity (KD
Fn/α5β1=1000 nM vs. KD
FnBPA-10/Fn/α5β1 = 260 nM) was due to an 
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Figure 25. SPR analysis of direct Fn-α5β1 interaction in the presence of FnBPA 
(A) Two-fold linear dilution series of Fn in HBS-T containing 1 mM MnCl2, and in the 
presence of (B) 1 µM of FnBPA-10, was injected over the α5β1 biosensor. (C) Higher Fn 
concentration series was used to measure Fn-α5β1 binding kinetics in the absence of 
MSCRAMMs. SPR response curves generated from Fn binding to α5β1 are shown in 
black, with a lower curve corresponding to a lower concentration of Fn injected. KD 
values for the Fn–α5β1 interaction (B and C) were obtained by fitting SPR response 
curves to a bivalent analyte binding model (fitted lines are shown in red), and kinetic 
parameters are listed in Table 2. No detectable binding when FnBPA-10 (1 µM) was 
injected over the same α5β1 surface (data not shown). 
 
 
 
increase in the initial association rate (ka1= 1.5 vs. 6.1 x10
4 M-1s-1). Interestingly, all other 
rate constants (kd1, ka2, and kd2) (Table 8) were similar across experiments, indicating that 
the α5β1 binding site in native Fn is the same as that for FnBPA-bound Fn. Because there 
is always a mix of conformers in the native Fn solution, the apparent association constant 
is the population-weighted average of association constants. The key point here is the 
binding affinity difference, not the absolute values of the binding affinities. 
3.14.3. Specificity of FnBPA-induced enhancement of Fn-α5β1 interaction 
To address the specificity of enhanced Fn-α5β1 activity and to further dissect the 
kinetic observations presented above, mixtures with varied FnBPA and fixed Fn 
concentrations were injected onto integrin (Fig. 26A and C). Again, a dose-dependent 
and saturable increase in the response was observed, similar to the results obtained in 
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Table 8. Kinetic parameters for Fn-α5β1 interactions 
Analyte 
 injected 
ka1 
(×104 M-1s-1) 
kd1 
(×10–2 s-1) 
ka2 
(×10–5 RU-1s-1) 
kd2 
(×10–3 s-1) 
KD 
(nM) 
χ 2 
 Fn alone 
1.5 ± 0.0 1.5 ± 0.0 1.1 ± 0.1 0.9 ± 0.0 1000 ± 130 1.15 ± 0.26 
 Fn + FnBPA-10 6.1 ± 0.6 1.5 ± 0.2 1.3 ± 0.3 1.0 ± 0.1 260 ± 90 1.10 ± 0.29 
 
Association (ka1, ka2) and dissociation rate (kd1, kd2) constants obtained from fitting SPR response curves 
(Fig. 25 B–D) to a bivalent analyte binding model. Statistical value χ2 is also listed to show the closeness 
of each fit. Values are mean values (with standard error in parentheses) obtained from at least three 
experiments. 
 
 
 
Figure 25B. Likewise, only the initial association rate ka1 was changed, while the stability 
of the complex (kd1), second-rate step (ka2 and kd2), and maximum response when all 
binding sites on active α5β1 were saturated (Rmax) were unaffected by the presence of  
FnBPA-10 (Fig. 26B). The initial association rate, ka1, was the only kinetic parameter 
directly affected by analyte concentration (units = M-1s-1). As the concentrations of Fn 
used in all experiments were the same, the observed increase in ka1 for Fn bound by 
increasing concentrations of FnBPA-10 likely represents an increase in the apparent 
concentration of the active integrin binding site (or active conformer) in native Fn. 
3.15. High-affinity FnBPA–FnNTD interaction is required for Fn activation 
Of the 11 Fn-binding repeats found in FnBPA, six were characterized as high-
affinity binders (FnBPA-1, -4, -5, -9, -10, -11). The higher affinity of these repeats has 
been attributed to their ability to interact with four sequential FnI modules of the FnNTD 
fragment.40 For example, while FnBPA-10 contains correctly spaced motifs to interact 
with 2–5FnI in a β-tandem zipper model of binding, the low-affinity repeat FnBPA-3 
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Figure 26. Kinetic components of the Fn-α5β1 interaction affected by FnBPA 
(A) Fn (50 nM) in the presence of an indicated concentration of FnBPA-10 was injected 
over a α5β1 surface on a Biacore sensor chip. (B) Kinetic components (ka1, kd1, ka2, and 
kd2) and Rmax obtained from local fitting were normalized to those of Fn alone and plotted 
as a function of FnBPA-10 concentrations. 
 
 
 
appears to lack the 5FnI interaction motif. Intriguingly, these particular Fn modules have 
been implicated in mediating long-range intramolecular contacts within native Fn dimers 
(Fig. 2).83-85 To understand whether the high-affinity interaction is required for the 
FnBPA-induced increase in Fn-α5β1 recognition, a panel of high and low-affinity FnBPA 
repeats was tested (Fig. 27). All studied high-affinity repeats (FnBPA-1, -5, -9, -10, and -
11) increased the Fn-α5β1 binding response, while the low-affinity repeat FnBPA-3 
exhibited a control-level signal. 
3.16. FnBPA enhances Fn–α5β1 integrin interactions in human plasma 
The SPR-based activity assay utilizing purified native and recombinant reagents 
enabled a quantitative kinetic assessment of the FnBPA-induced enhancement of Fn-α5β1 
binding. Next, whether this effect could be recapitulated using human plasma as a source 
of native Fn was investigated. Indeed, a FnBPA-dependent increase in plasma Fn-α5β1 
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Figure 27. Relationship of FnNTD interaction and α5β1 integrin activation 
SPR sensorgrams were generated by injecting 50 nM Fn in the presence of GST-fused 
FnBPA repeats (0.5 µM for high-affinity repeats FnBPA-1, -5, -9, -10, -11 and 15 µM 
for low-affinity repeat FnBPA-3) over immobilized α5β1. KD values reported for direct 
binding of FnNTD by high-affinity FnBPA repeats are provided for reference and were 
obtained from previously published ITC experiments.40 Weak affinity between FnBPA-3 
and FnNTD was measured by SPR (data not shown). None of the repeats bound directly 
to α5β1 (data not shown). 
 
 
 
binding was observed with FnBPA-10, when purified native Fn (Fig. 28A) and 
unpurified intact Fn in 5% human plasma (Fig. 28B) were used in an ELISA-type 
binding assay. Interestingly, the activation of integrin αIIbβ3 was less specific for intact Fn 
in plasma compared to α5β1, although they both recognized the = RGD site, suggesting 
possible involvement and fine tuning of the synergistic site on Fn by α5β1 binding. 
3.17. Disease-related polymorphisms in FnBPA affect Fn-binding activity 
SPR was also used to investigate the direct interactions between Fn and peptide 
variants synthesized to mimic FnBPA-9 of FnBPA from clinical isolates of S. aureus: 
H782A+K786A, H782Q+K786N, H782Q+K786I, H782A, H782Q, K786I, and a wild- 
type peptide (H782+K786). 
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Figure 28. Effect of FnBPA on intact Fn in plasma for integrin binding 
In an ELISA type assay, FnBPA-10 peptide was pre-incubated with (A) 0.2 µM purified 
Fn, and (B) 5% human blood plasma, and then added to integrin-coated wells. Bound Fn 
was probed with anti-Fn pAb. 
  
 
 
Figure 29 shows the sensorgrams of the binding of FnBPA-9 peptides to FnNTD, 
and the curves were fit with a two-state binding model to calculate the kinetic parameters 
(Table 3). This model was chosen based on the zipper type of binding that involves the 
conformational transition of the peptide from disordered to ordered.37 The two-step 
binding model includes (i) the initial binding of the peptide to the FnNTD (A + B ↔ AB) 
followed by (ii) a conformational change to form a more stable complex (AB ↔ AB*). 
This model reproduced the experimental SPR sensorgrams better than the 1:1 Langmuir 
model and also described the interaction between FnBR9 and FnNTD. The binding 
affinity for the interaction between FnBR9 wild-type peptide and FnNTD (KD = 0.66 
µM) is similar to the KD value of 0.5 µM for the interaction between the 19-mer FnBR1 
peptide and 2FI3FI detected by NMR chemical shifts 37. All peptides contained the same 
recognition motifs (G783 and EDT795) to interact with 
2FI3FI, which was indicated by the 
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Figure 29. SPR analysis of interactions between FnBPA-9 peptides and FnNTD 
Two-fold linear dilution series of the peptide, at the indicated concentration range, were 
injected over the immobilized FnNTD. SPR response curves generated from peptide 
binding are shown as colored lines, with a lower curve corresponding to a lower 
concentration of peptide injected. Sensorgrams were globally fit to a 1:1 Langmuir 
model to obtain KD or to a two-state reaction model to obtain apparent dissociation 
constants (KD
app) for the interaction (fit lines are shown in black). Kinetic parameters are 
listed in Table 9. 
 
 
 
overall similar responses for peptides binding to FnNTD. Upon binding, FnBPA-9 
underwent a conformational transition from disordered to a β-strand, complementing the 
β-sheet structure in FnNTD. As a result, bound FnBPA-9 formed a large intermolecular 
surface and stable complex with FnNTD.40 
Table 9 lists the kinetic and affinity constants obtained from fitting (Fig. 29). 
Within the two-step processes, the progression of the second step is more than 18-fold 
slower than the first dissociation step (ka2 vs. kd1), suggesting that the conformational 
change step is rate-limiting for the generation of a stable complex. The mutations at 
positions H782 and K786 with disease-associated SNPs result in ~20-fold stronger 
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Table 9. Kinetic parameters for FnBPA-9 peptides binding to FnNTD 
 
Peptide 
ka(1) 
(x105 M-1s-1) 
 Kd(1) 
(x10-1 s-1) 
ka2 
(x10-3 s-1) 
kd2 
(x10-2 s-1) 
KD or KDapp 
(µM) 
KD1 
(µM) 
kd1/ ka2 
H782A+K786A 0.54 ± 0.07 3.20 ± 0.04   6.04 ± 0.81   
H782A 0.73 ± 0.19 3.22 ± 0.29   4.52 ± 0.81   
H782Q 0.62 ± 0.07 2.05 ± 0.21   3.35 ± 0.71   
H782Q+K786N 1.74 ± 0.11 4.02 ± 0.24 11.5 ± 1.13 1.03 ± 0.04 1.10 ± 0.04 2.31 ± 0.07 35 ± 4 
Wild type 2.23 ± 0.44 2.70 ± 0.52 10.3 ± 0.42 1.23 ± 0.18 0.66 ± 0.06 1.21 ± 0.10 26 ± 4 
H782Q+K786I 4.87 ± 1.30 3.07 ± 0.86 6.55 ± 0.40 2.47 ± 0.38 0.50 ± 0.10 0.64 ± 0.13 46 ± 11 
K786I 5.05 ± 1.31 1.57 ± 0.17 8.70 ± 0.64 1.07 ± 0.10 0.18 ± 0.05 0.32 ± 0.08 18 ± 2 
 
 
 
binding affinity than the alanine substitutions (KD
app value = 0.18 µM for K786I, 
compared to 6.04 µM for H782A+K786A). The enhanced affinity of K786I for FnNTD 
is due to the increased affinity of initial binding step (KD1), with a higher on-rate and 
slower off-rate and a favorable conformational change indicated by the smaller value of 
ratio kd1/ka2. The intrinsic disorder FnBR forms a fuzzy complex when it binds to Fn,
86 
where some of the disordered region is maintained upon interaction with Fn, directly 
impacting biological function.86 Even though the ligand-binding motifs of FnBPA-9 are 
intact, the changes in the regions flanking the motifs can influence ligand binding by 
fine-tuning the kinetics of the reaction. This provides a mechanistic explanation for the 
association of H782Q+K786I SNPs in S. aureus FnBPA in patients with persistent 
bacteremia,25 where fast adherence to and invasion of host cells may be enhanced by fast 
association and conformational changes that expose cryptic integrin sites in Fn,87 while 
H782Q+K786N is associated with patients with infected cardiac device implants in 
which invading host cell and rapid attachment are not critical for pathogenesis. 
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CHAPTER IV  
DISCUSSION 
 
Many studies have shown that the virulent properties of FnBPA depend on tight 
and multivalent binding to Fn,88-90 and in some cases, cooperative binding to Fg.12-13 
Structural and mechanistic characterizations have been carefully conducted for 
interactions of FnBPA and Fn,39-40 and a structure of FnBPA bound to the previously 
identified single target site in Fg was recently reported.28 However, most in vitro studies 
were completed with domains or segments of the proteins. The host protein interactions 
with the full-length FnBPA presented on the surface has not been characterized to date. 
The mechanism by which multifunctional FnBPA unifies the Fg- and Fn-binding 
capacities are still unclear. One challenge is that FnBPA contains a large portion of 
repetitive disordered segments, making it difficult to clone and express. The large size 
and multiple domains of Fn and Fg molecules also create complexity for bioanalytical 
binding measurements. In this study, I utilize SPR technology to explore the FnBPA 
interaction in a non-pure system (blood plasma) and then use native purified proteins and 
domains to investigate complex binding. Using both solid phase and solution phase 
analyses, this work studied, in molecular detail, how surface-anchored full-length 
FnBPA binds to Fn and Fg, as well as the interplay and regulation of these interactions. 
The biochemical characterization of FnBPA binding with Fn and Fg indicates 
that both interactions are strong with quick recognition (fast on-rate) and stable bonding 
(slow off-rate). These measurements confirm biological functions, as FnBPA is 
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expressed at a low density (log phase during growth), and the highly adhesive and 
invasive properties will become necessary for bacteria to establish colonies. FnBPA on S. 
aureus infecting different positions in the human body is exposed to very different 
external forces, ranging from the dynamic shear force (blood flow) associated with 
endovascular environments to more static conditions in the anterior nares. Different 
conditions may select for FnBPA adhesin with rapid and strong binding attributes. 
Strong binding of FnBPA to Fn mediates the attachment of S. aureus to the 
endothelium under dynamic conditions. This also leads to allosteric activation of integrin 
binding sites in Fn, which, in turn, are recognized by α5β1 integrin on the endothelial 
surface, triggering bacterial uptake. Many earlier studies showed that FnBPA binds 
weakly to Fg via a linear sequence (about 15 aa) in the C-terminus of the Fg γ-chain 
(FgγC peptide), but this study provides evidence suggesting that this primary site has to 
engage with additional sites in Fg to achieve a strong interaction. Multiple contacts 
between FnBPA and Fg are possible, and they presumably involve molecular 
rearrangements within each protein. As a result, it is possible that residue changes in 
critical areas of FnBPA could influence ligand binding. 
The work accomplished in this dissertation is significant. It provides critical 
insights into the interactions between MSCRAMM and host proteins regarding overall 
affinity, active conformation, and effects on host protein structure/function. It correlates 
a molecular interaction study with clinical outcomes, and it also improves scientific 
knowledge and technical capability in the field of adhesin-mediated host-pathogen 
interactions. 
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4.1. SPR for studying binding of surface-associated protein 
SPR is a unique technique for studying binding interactions because of the 
determination of the binding affinity and kinetics, and for direct observing the binding 
dynamics in real time. Capture of tagged recombinant proteins is an attractive approach 
for protein attachment in the SPR-based Biacore systems since physiological conditions 
can be used during the whole procedure. Also, the capture of tags generates a directed 
structural orientation of the protein on the surface, potentially offering optimal site 
exposure. In the present study, a receptor sensor was created to mimic the same surface 
orientations of the molecules studied, for example, FnBPA on the bacterial surface and 
integrin receptor on host cell surface. This approach enables the assay condition for 
binding kinetics and affinity measurement that is more relevant to the physiological 
condition. 
Previous in vivo study of Fn and Fg binding to Lactococcus lactis expressed 
FnBPA suggested the functional versatility may be partly related to the location of the 
protein, in which the in vivo conformation of surface-bound FnBPA may be different 
from that of unbound recombinant proteins.13 The results of the present study provide 
experimental evidence to support this hypothesis. On the surface of the staphylococci, 
FnBPA is anchored to the cell wall at its C-terminus, with the Fg binding domain 
extended from the surface. To mimic FnBPA surface orientation, a Biacore method was 
developed to capture FnBPA through its C-terminal His-tag onto α-his mAb surface. 
Host ligands in solution (purified proteins or non-purified plasma) was injected onto the 
functionalized FnBPA sensor. The results from the binding analysis indicate that binding 
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of soluble Fg to surface-anchored FnBPA is ~50-fold stronger than soluble FnBPA 
binding to immobilized Fg (KD values of 15.7 ± 5.6 nM and 725 ± 74 nM, respectively. 
Fig. 9A and D, and Table 4). Even when both FnBPA and Fg are in solution, the affinity 
detected by ITC is 230 ± 80 nM, still 15-fold weaker than surface-bound FnBPA. 
Furthermore, when physiological materials and conditions are applied, SPR with 
functionalized sensor approach can provide valuable kinetic insights into what or how 
the pathogen and host see each other. Sometimes, the individual ligand-binding events in 
isolation cannot explain the measured outcome from the non-purified system. For 
example, the results in Fig. 7, 8 and 20 demonstrate that blood plasma is far more potent 
reactant than purified Fg/Fn alone or combined, and likely Fg alone in plasma does not 
react with FnBPA but only when it is complexed with Fn. A new hypothesis will have to 
be tested. 
4.2. New binding sites in Fg and FnBPA 
In this study, the binding analysis and structural characterization of FnBPA 
indicate that Fg conformation and structural orientation of FnBPA are critical for Fg–
FnBPA interaction. By comparing FnBPA binding activity of different forms of Fg 
molecule, such as plasma (extremely tight binding and not dissociated molecule 
observed), soluble Fg (KD = 10 nM, Fig. 7), amine immobilized Fg (KD = 780 nM, Fig. 
9), FgD (KD = 86 nM, Fig. 9), FgD dimer (FgγC inactive form, KD = 163 nM, Fig. 9), 
and FgγC peptide (KD = 1.82 µM, Fig. 17), it is clear that other binding sites in Fg may 
participate in the observed strong FnBPA recognition. Both Fg and minimal binding 
domain FnBPA38–550 are negatively charged at physiological pH, with pI values of 5.5 
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and 5.0 (Table 5) respectively. So their high-affinity electrostatic interaction (Fig. 13) 
was unexpected since the previous identified FgγC peptide interaction was hydrophobic 
in nature. The C-terminus of α chain, located next to the FgD domain, may act as a 
potential binding site, as it is positively charged at pH 7.4. 
Recently, it was found that in addition to its originally identified FgγC peptide, 
ClfA A domain binds to another distinct site in Fg.91 The structure of a blocking 
monoclonal antibody in complex with the N2N3 domain of ClfA revealed that the 
epitope for the mAb is located on “top” of N3 but does not affect N2N3 cleft where FgγC 
peptide binding site is located. Molecular modeling identifies the partially overlapping 
N3 epitope for the mAb to be the second Fg-binding site.91 Since ClfA and FnBPA are 
structurally and functionally related MSCRAMMs, it is likely that FnBPA binding to Fg 
also involves a two-site mechanism. Among S. aureus isotypes, FnBPA sequence 
diversity is found most divergent in N3 subdomain24 (Fig. 1). It is reasonable to speculate 
that N3 is exposed to contact with the host ligand Fg and subjected to selective pressure 
to carry out functions. Overall, the mechanism of Fg binding to FnBPA is more 
complicated than originally proposed and more so than prototype Fg-ClfA interaction. 
The absence of “latching” event due to the potential overlap between residues in FnBPA-
1 (or linker between N3 subdomain and FnBR, Fig. 1) affected by Fg and Fn binding. It 
seems that these two ligand-binding events are coupled and influence each other, making 
multifunctional FnBPA unique in response to host environment (salt, pH, and ligand 
concentration) change. 
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4.3. Function of N1 domain 
Subdomain N1 of the A domain is highly conserved among different FnBPA 
isotypes (Fig. 1),24 suggesting functional importance. Even though the structure and 
function of the N1 domain are unknown, it is reasonable to speculate that N1 serves as a 
regulatory domain through intramolecular interactions (e.g., with the distant FnBR 
region) within FnBPA. There are several lines of evidence that support the proposed N1 
fold-back structure and function: first, specific residues (Q139 and Q141) in N1, far from 
the C-terminal FnBR, are involved in Fn cross-linking,92 suggesting engagement with 
FnBR (Fig. 1). Second, a short sequence within N1 is required for surface expression of 
FnBPA, which contains the disordered FnBR region.29 Third, data from this study 
suggest that proteolytic removal of N1 could regulate Fg-binding activity, suggesting a 
regulatory role of N1. Fourth, it is possible that serine proteinase cleavage of FnBPA on 
the cell surface occurs in vivo either via thrombin from the host or the S. aureus 
coagulase-prothrombin complex.93 Fifth, the previous study identified Gln139 in the N1 
subdomain of FnBPA as a major cross-linking site in the factor XIIIa-mediated reaction 
with α chains of Fg.94 Therefore, the question of whether N1 could fold-back toward 
N2N3 subdomains to form an optimal conformation for Fg binding was investigated. 
Surprisingly, when comparing the N1 sequence with the Fg -chain, N1 contains a 
similar amino acid sequence to the 17-aa FgC peptide (highlighted in blue in Fig. 30) 
The FgC peptide binds to the cleft between the N2 and N3 subdomains of FnBPA, and 
it is likely that a similar sequence in N1 can fold back to occupy the hydrophobic cleft 
through intramolecular interactions. If this holds true, the interaction could also occur  
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Figure 30. Sequence comparison of N1 and FgγC region 
Sequence from N1 of FnBPA (FnBPA120–168) compared to the C-terminal ends of two Fg 
-chain isoforms (Fg and elongated variant Fg’). The 17-aa FgC peptide sequence is 
highlighted in blue. 
 
 
 
between molecules to promote dimerization of surface FnBPA on neighboring cells, a 
possible mechanism for the protein-based biofilm30 of S. aureus. An Experiment is 
underway to test this possible interaction using a synthetic N1 peptide. 
4.4. Modeling FnBPA–Fg interaction 
Fluorescence and CD spectroscopy analyses of the full-length FnBPA confirmed 
that the protein is composed of both compact and disordered regions. It is possible that a 
non-linear structure existed in full-length FnBPA, in which the N- and C-terminal 
disordered regions wrap around or closely associate with the structured A domain. These 
results also suggest that the original A domain assignment, which included N1 and 
FnBPA-1, is the most relevant functional ligand-binding domain. By correlating this 
solution structure with the ligand-binding activity of FnBPA proteins measured by SPR, 
the results imply that the N1 and FnBPA-1 regions may be involved in maintaining an 
appropriate FnBPA fold. This active FnBPA provides an optimal conformation for rapid 
ligand recognition and the formation of more stable complexes, resulting in tighter Fg 
binding. Based on this observation and the N1 function revealed in this study, as well as  
 78 
 
 
Figure 31. Selective binding model of FnBPA–Fg interaction 
Surface-anchored FnBPA is in a dynamic equilibrium between (A) unfolded and (B) 
fold-back conformations because of intramolecular interactions between the N1 region 
and hydrophobic cleft between N2N3 subdomains. Fold-back form could be further 
stabilized by C-terminal FnBR region and represent the active conformation, with a 
preformed binding site ready for a strong interaction with soluble Fg. Low pH and high 
salt conditions or N1 removal by thrombin shift the equilibrium to the inactive 
conformation, making the Fg interaction unfavorable. On the host side, soluble Fg dimer 
exists in blood as an assemble of different conformers. Under high shear flow conditions, 
only a small portion of these conformers can rapidly recognize FnBPA (or low 
concentrations of active Fg for FnBPA binding), presumably through exposed N3 surface 
binding to structured Fg domain, but not through the disordered FgγC region (C). This 
initial strong recognition of N3 may cause rearrangement of N2N3 orientation and unfold 
N1 from the cleft. The unoccupied cleft is then ready to accommodate FgγC in the 
proximity (D). Alternatively, the high local concentration of FgγC, achieved through 
initial binding or high concentration of Fg in the blood, induces competition between 
FgγC and N1 to bind the cleft region of FnBPA. N2N3 domain structures (apo and in 
complex with FgγC) are from published data.28 
 
 
 
the existing N2N3 structure, I propose a Fg-binding model for FnBPA (Fig. 31).  
The surface-anchored FnBPA is not a rigid structure, but a dynamic equilibrium 
between unfolded and folded conformations. This is because the dynamics of the 
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intramolecular interaction allow N1 to fold-back and occupy the hydrophobic cleft 
between N2N3 subdomains. The fold-back form could also be further stabilized by the 
C-terminal FnBR region and represents the active conformation, with a preformed 
binding site, ready for a strong interaction with soluble Fg. The low pH or high salt 
conditions or N1 removal by thrombin will shift the equilibrium to the inactive 
conformation, making the Fg interaction unfavorable. On the host side, soluble Fg 
dimers exist in blood as an assembly of different conformers. Under high shear flow 
conditions, only a small portion of these conformers can rapidly recognize FnBPA (or a 
low concentration of active Fg for FnBPA binding), presumably through exposed N3 
surface binding to structured Fg domain, but not through the disordered FgγC region. 
This initial strong recognition of N3 may cause rearrangement of N2N3 orientation and 
unfold N1 from the cleft. The unoccupied cleft is then ready to accommodate a proximal 
and available FgγC molecule. Alternatively, the high local concentration of FgγC, 
achieved with initial binding or high concentration of Fg in the blood, can compete with 
N1 for binding to the cleft region of FnBPA. 
4.5. Modeling allosteric activation of Fn–integrin by FnBPA 
Results from DLS (Table 7), CD (Fig. 22), and FRET (Fig. 23) measurements 
indicate a conformational rearrangement of Fn involving domains distant from the 
FnBPA binding site. SPR experiments demonstrate a significant enhancement of Fn-α5β1 
integrin affinity in the presence of FnBPA (Fig. 25). Detailed kinetic analyses of these 
interactions reveal that this change in affinity can be attributed solely to an increase in 
the initial Fn-α5β1 on-rate (Fig. 26), and this rate enhancement depends on high-affinity 
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Fn-binding by FnBPA (Fig. 27). These data implicate MSCRAMM-induced perturbation 
of specific intramolecular contacts within the Fn heterodimer, resulting in activation by 
exposing previously cryptic α5β1 interaction motifs. By manipulating the conformation of 
key Fn functional domains, FnBPA enables S. aureus to hijack normal host physiology. 
Enhanced Fn-α5β1 interactions lead to the recruitment of focal contact-associated 
proteins, and subsequent integrin clustering at a bacterial attachment site initiates 
intracellular signaling through the focal adhesion kinase (FAK) and Src kinases.60, 95-96  
Together, these experiments provide a detailed structure–activity relationship of 
FnBPA–host interactions and strongly suggest an allosteric mode of Fn-α5β1 affinity 
enhancement for FnBPA (Fig. 32). I speculate that dimeric native Fn exists as an array of 
conformers in solution. At equilibrium, the predominate forms of Fn are compact and 
sterically occlude α5β1 interaction domains (9-10FnIII) by long-range intramolecular 
interactions, thereby impeding Fn-α5β1 recognition. The equilibrium of Fn conformers 
shifts upon high-affinity binding of FnBPA, and native intramolecular contacts are 
disrupted, exposing previously cryptic α5β1 binding sites and promoting Fn-α5β1 binding. 
Domains involved in integrin binding by Fn are located at a site distant from the FnBPA 
binding site. Therefore, a critical feature of FnBPA-induced activation of Fn-α5β1 is 
allosteric modes of host protein modulation, which have been previously reported for S. 
aureus.97 By correlating structural changes in Fn (Fig. 23) to direct measurements of 
increased Fn-α5β1 affinity (Table 8), this work significantly advances our understanding 
of the structural basis of modulation of integrin function by Fn-binding MSCRAMMs. 
Interestingly, polymorphisms have been recently reported in high-affinity FnBPA 
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Figure 32. Model for allosteric enhancement of Fn-α5β1 binding by FnBPA 
Fn is represented in the native state (left) or bound by FnBPA (right). Model of native 
Fn, including intermolecular contacts, was adapted from a previously proposed model 
based on multiple independent studies. In a native state, major solution conformations of 
Fn occlude the canonical α5β1 interaction motifs located in the 9–10FnIII domains. Upon 
binding to Fn, FnBPA disrupts specific intermolecular contacts in the N-terminal domain 
of Fn (FnNTD), resulting in global structural rearrangements at sites distant from the 
FnBPA binding site. Previously cryptic integrin interaction sites are exposed, promoting 
interaction of Fn with α5β1. This initiates “outside-in” signaling events, leading to 
cytoskeletal rearrangement and eventual internalization of Fn-coated S. aureus. 
 
repeats (Fig. 1), and S. aureus strains that harbor these mutations are highly correlated 
with infection of cardiovascular devices.22, 25 How these FnBPA mutations impact bound 
Fn tertiary structure is currently unknown. However, I predict that sequence changes to 
 82 
 
residues in FnBPA repeats could result in different global Fn structures and thus 
functions. 
Some studies have shown that surface induced unfolding of Fg promotes integrin 
αMβ2 (Mac-1) receptor activation and inflammation.98 A high-affinity Mac-1 binding site 
existed in the C-terminal tail region of the Fg γ chain, but it is buried and protected 
within the hydrophobic core of the protein.99 One primary αMβ2 binding sites, P2 (Fgγ377–
395), is located next to FnBPA binding site.
100 Allosteric activation of the Fg-receptor 
interaction by FnBPA could also generate the strong Fg binding demonstrated in the 
study. It is very likely that Fg unfolds on FnBPA surface, and FnBPA-bound Fg interacts 
with αMβ2 receptors. 
4.6. Modeling FnBPA-dependent S. aureus host interactions 
From commensal to infectious states, the S. aureus host interaction involves a 
complex interplay of many different proteins and events. First, cells must recognize each 
other, adhere to one another, and create an interface through which a biological signal 
can be generated, ultimately producing a specific outcome that leads to the initiation of 
bacterial adhesion, host defense, bacterial invasion, or gene regulation. In light of the 
discoveries described in this dissertation and the possible functions in disease process38, I 
propose a model (Fig. 33) to summarize multi-faceted FnBPA-dependent ligand binding, 
activation, and host cell signaling. (1) S. aureus utilizes the cell wall surface protein 
FnBPA to bind directly to the Fn and Fg in tissue, Fn/Fg-coated medical devices, or 
thrombus containing Fg/Fn. The high-affinity and avidity interactions between two 
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Figure 33. A Model for FnBPA-mediated S. aureus host interaction 
(A) Surface-associated FnBPA (both unfolded and fold-back forms) can bind directly to 
Fn and Fg in tissue ECM, Fn/Fg-coated medical devices, or thrombus containing Fg/Fn . 
High-affinity and avidity interactions between two surfaces ensures the firm attachment 
of S. aureus to the host site. (B) Circulating plasma Fg and Fn can rapidly and firmly 
adsorb onto the bacterial surface via FnBPA. Fast binding and high-affinity ligand Fn is 
likely the first molecule adsorbed to FnBPA via one or more specific FnBR, 
allosterically activating A domain and exposing N2N3 cleft for Fg binding. (C) FnBPA-
bound Fn and FnBPA-bound Fg are activated and exposed to integrin binding sites, 
triggering integrin signaling in endothelium and immune cells. Location of an array of 
high-affinity Fn-binding repeats close to the bacterial cell wall enables the establishment 
of intimate contact with the host cell. FnBPA-bound Fg and Fn can also engage different 
integrins for cross-talk, resulting in more robust activation of the signaling network. (D) 
Dimeric nature of Fn and Fg enables functionality as bridging molecules between surface 
FnBPA on S. aureus and cells, leading to the formation of extensive adhesive contacts 
for a protein-based biofilm community. 
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surfaces ensure the firm attachment of S. aureus to the host site. (2) Circulating plasma 
Fg and Fn can rapidly and firmly adsorb onto the bacterial surface via FnBPA. The fast 
binding and high-affinity ligand Fn is likely one of the first molecules to be adsorbed to 
FnBPA via one or more specific FnBR, allosterically activating the A domain and 
exposing the N2N3 cleft for Fg binding. (3) FnBPA-bound Fn and Fg are activated and 
exposed to integrin binding sites to trigger integrin signaling in endothelium and immune 
cells. The location of an array of high-affinity Fn-binding repeats close to the bacterial 
cell wall enables the establishment of intimate contact with the host cell. It is also 
possible that FnBPA-bound Fg and FnBPA-bound Fn can engage different integrins for 
cross-talk, resulting in more robust activation of the signaling network. This appears to 
confer an advantage to S. aureus, by facilitating immune evasion and serving as a 
bacterial reservoir in chronic infections.54, 60 (4) The dimeric nature of Fn and Fg enables 
their function as bridging molecules between surface FnBPA on S. aureus, along with 
the A domain-mediated self-association of FnBPA, and between cells. Host factor XIIIa-
catalyzed cross-linking reactions can further stabilize this network and contribute to 
biofilm development. 
4.7. Future studies 
To gain a true mechanistic understanding of FnBPA and host ligand interactions, 
the relevant complexes should be reconstituted and their three-dimensional structures 
determined, to reveal the molecular mechanisms of the interactions. The initial 
crystallization trials of the minimal domain (FnBPA38–550) and the minimal domain in 
complex with FgD indicated that the unstructured region in N1 needs to be further 
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removed. Although thrombin-treated FnBPA (FnBPA166–981) altered Fg binding, the 
partial interaction still remained. Recombinant FnBPA166–550 and constructs with an 
extended N-terminus can be used for future crystallization studies. 
The binding study of disease-related polymorphisms in FnBPA only focused on 
the Fn-binging region (FnBR) of FnBPA. Considering that the multifunctional role of 
FnBPA is important during the disease process, in which both Fg- and Fn-binding 
synergistically initiate attachment to endothelium, and multiple Fn-binding events can 
activate the integrin for host cell invasion. Variant sequences found in FnBRs are 
associated with variations elsewhere in the protein, for example, the Fg-binding A 
domain, which is known to have greater sequence diversity.24 By measuring the ligand-
binding characteristics (kon and koff, affinity, and stoichiometry) of recombinant full-
length FnBPA from clinical isolates that carry disease-related variations and comparing 
them with wild-type FnBPA, a mechanistic explanation for the clinical outcomes 
observed can be generated. 
The bioanalytical SPR and adhesin functionalized biosensor platform can be used 
as an assay system for screening and developing therapeutics and biologics, such as 
small molecules or antibodies from healthy or infected populations. 
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CHAPTER V  
CONCLUSIONS 
  
The S. aureus surface protein FnBPA is essential for S. aureus adhesion and 
invasion of host cells. In this study, I applied a set of biochemical and biophysical 
methods (CD, DLS, fluorescence spectroscopy, FRET, ITC, and SPR) to investigate 
FnBPA and probe structure–activity relationships of FnBPA-dependent host interactions. 
Based on the results presented in this dissertation, the following conclusions are made. 
First, circulating plasma Fn and Fg can bind simultaneously and tightly to surface-
anchored full-length FnBPA. Second, several physiologically relevant factors, such as 
proteolytic processes, ionic strength, and pH, can affect the fold-back conformation of 
the N1 subdomain of FnBPA, resulting in altered Fg binding. Third, the strong 
interaction between FnBPA and Fn induces conformational changes in Fn at distant sites, 
resulting in exposed cryptic integrin binding sites and enhanced Fn ̶ α5β1 interaction. 
Fourth, disease-causing polymorphisms in FnBPA may impart conformational variability 
to the ligand complex, which affects adhesion reactions and attachment. Finally, this 
study demonstrates that SPR with a functionalized biosensor is an effective technique to 
study interactions between bacterial surface proteins and host ligands.  
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